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Metabonomics examines the dynamic multiparametric metabolic response of 
living systems to pathophysiological stimuli. The metabolic phenotype 
(metabotype) provides unique information that is complementary to genomic, 
transcriptomic or proteomic profiles. Although metabonomic analysis has been 
applied in a wide range of medical disciplines such as oncology, neuroscience and 
toxicology, there are few published studies on eye diseases. This thesis explores 
the potential of metabonomics in the study of eye diseases and is divided into the 
following chapters. 
 
1. Characterisation of the Human Tear Metabolome 
The tear film is an accessible biological source in studying ocular surface disorders 
as it is directly associated with the corneal surface. The collection of tears is also a 
non-invasive procedure that facilitates large-scale clinical studies. A 
characterisation of the human tear metabolome is essential before the diagnostic 
potential of the tear film can be exploited. Human tear fluid was analysed with 
untargeted information-dependent acquisition (IDA) liquid chromatography 
tandem mass spectrometry (LC-MS/MS). Using isotope pattern-matched peak 
mining, 60 metabolites were detected in human tears. Among these, 43 
metabolites were reported for the first time in tear fluid. 
 
2. Combined Metabonomic and Proteomic Analysis of an In Vitro 
Model of Dry Eye Disease 
Most studies that investigated the mechanisms of hyperosmolarity-induced cell 
damage in dry eye disease using in vitro and clinical models were focused on the 
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analysis of mRNA transcripts and proteins. The metabolome comprises complete 
set of small molecule metabolites (such as metabolic substrates, intermediates and 
secondary metabolites) where its fluxes are reflective of downstream level cellular 
processes. The metabolome could potentially reveal complementary information 
to the transcriptome and proteome, aiding the understanding of dry eye 
pathology. Using global metabonomic profiling, glycerophosphocholine was 
identified as the preferred osmoprotectant in human conjunctiva epithelial cells, 
over other osmoprotectants such as carnitine and betaine. Increased synthesis of 
UDP-N-acetylglucosamine and activation of the hexosamine pathway were 
confirmed via proteomic analysis. As O-linked protein glycosylation with UDP-N-
acetylglucosamine is a rapid survival response, modulating glycosylation levels in 
ocular surface tissues could be important in reducing apoptosis in dry eye disease. 
 
3. Plasma Metabotyping of Diabetic Retinopathy  
Diabetic retinopathy (DR) is the most common microvascular complication of 
diabetes and the leading cause of visual impairment in working adults worldwide. 
Diabetic patients often develop DR despite control of risk factors, suggesting the 
involvement of the metabolic memory effect. Recent metabonomic studies have 
uncovered plasma/sera metabolic signatures associated with or predictive of 
impaired glucose tolerance and diabetes. Given DR is a complex disease where 
findings from genome-wide association studies have not been conclusive, we 
postulate that there could be a metabolic signature of DR, and that this signature 
could be resolvable from diabetes. Plasma samples collected from the Singapore 
Indian Eye Study were analysed using gas chromatography-time-of-flight mass 
spectrometry (GC-TOF-MS). 1,5-Gluconolactone, 2-deoxyribonic acid, gluconic acid 
 xi 
and urea were identified as metabolite markers of DR independent of clinical risk 
factors. 
 
4. Investigation of SWATHTM MS for Metabonomic Analysis 
In addition, a short fourth chapter describes the investigation of using a novel mass 
spectrometry acquisition method, Sequential Window of All Theoretical Fragment 
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1.1. Overview of Metabonomics and Analytical 
Platforms 
 
The term “metabonomics” was first introduced by Prof. Jeremy Nicholson (1). It is 
defined as the quantitative measurement of the dynamic multiparametric 
metabolic response of living systems to pathophysiological stimuli. The related 
term “metabolomics” on the other hand, referred to the unbiased identification 
and quantitation of metabolites in a system, with a focus on maximising the 
coverage of metabolites within an analytical platform (2). The terms 
“metabonomics” and “metabolomics” are now used interchangeably refer to the 
global quantitative analysis of metabolites in relation to health and disease (3). 
 
As metabolites are the end products of regulatory processes, the metabolome is a 
better representation of the phenotype and offers insights complementary to the  
genome, transcriptome or proteome (3).  Thus metabonomics is especially suited 
to study conditions without strong genetic associations, or conditions with strong 
environmental contributions. 
  
The main analytical techniques adopted in global metabonomic analysis are 
nuclear magnetic resonance (NMR) spectroscopy, gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) (4). 
Both NMR spectroscopy and GC-MS offer high reproducibility and straightforward 
identification of metabolites (through extensive spectra libraries integrated into 
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data processing software). In addition, NMR spectroscopy is non-destructive, 
requires minimal sample preparation and allows absolute quantitative data to be 
obtained simultaneously. However, NMR spectroscopy is the least sensitive of the 
three techniques and may be biased towards the detection of high abundance 
metabolites. Electron ionisation (EI) in GC-MS is highly robust and reproducible, 
thus enabling the use of spectral libraries in the identification of metabolites. The 
deconvolution function, a common feature in data processing software, also 
facilitates spectral resolution of co-eluting metabolites which is not possible by 
visual inspection of the chromatogram (5). However, the technique may be prone 
to confounding factors (6) introduced through the sample derivatisation process or 
thermal degradation of metabolites at elevated temperatures.  
 
More recently, LC-MS has emerged as a complementary metabonomic technique 
addressing the limitations of NMR spectroscopy and GC-MS. Although LC-MS is 
highly sensitive and capable of detecting a wide range of metabolites, the 
technique is susceptible to retention time (RT) drift and matrix effects related to 
electrospray ionisation (ESI) (7, 8). In addition, ESI also results in the formation of 
adducts, dimers and in-source fragment product ions (collectively termed 
redundant signals) alongside [M+H]+/[M−H]− parent ions, further confounding data 
analysis and metabolite identification. ESI is also variable among samples analysed 
on the same instrument in a large batch (9) and fragmentation patterns in tandem 
mass spectrometry (MS/MS) differ between instruments that apply different 
mechanisms of ion activation (10). The identification of unknown metabolites 
detected on LC-MS is limited by the coverage of mass spectra libraries (10). 
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1.2. Metabonomic Studies in Ocular Fluids and Tissues 
 
While clinical applications of metabonomics in literature encompass a wide range 
of medical disciplines such as oncology (11), neuroscience (12) and toxicology (13), 
there are few reports of metabonomics studies on eye diseases. A summary of 
metabonomic studies on ocular disorders in literature thus far is shown in Table 
1.1.  The majority of these studies had used 1H-NMR as the analytical platform. 
From the current database statistics (14) of the Human Metabolome Database 
(HMDB) (15), over 4500 metabolites have been detected in blood but less than 100 
metabolites are known in the aqueous humour and tear fluid. A summary of 
studies that have profiled the metabolome of ocular fluids and tissues is shown in 
Table 1.2.  
 
A review of the literature thus far has identified several areas of investigation for 
the application of metabonomic analysis in studying eye diseases, namely (i) the 
development of untargeted liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) platforms for metabonomic applications, (ii) expansion of the known 







Table 1.1 Metabonomic studies on ocular disorders in literature. 




UV Irradiation Rabbit Cornea  1H-NMR  (16) 
Uveitis  Human Vitreous Humour  1H-NMR  (17) 
Dry Eye  Human Reflex Tears  1H-NMR  (18) 
Supplements on Dry Eye Human Reflex Tears  1H-NMR  (19) 
Glaucoma Model  Rat Aqueous Humour  1H-NMR  (20) 
Diabetic Retinopathy  Human Vitreous Humour  1H-NMR  (21) 
Diabetic Retinopathy  Human Plasma  GC-MS  (22) 
 
 
Table 1.2 Studies profiling the metabolome of ocular fluids and tissues in 
literature. 





Human Aqueous Humour  1H-NMR  13  (23) 
Rat Lens  LC-MS (TOF), 1H-NMR  42  (24) 
Human Tears, Aqueous 




1.3. Thesis Objectives and Scope of Work 
 
1.3.1. Specific Objectives 
The objectives of this thesis are: 
1. To characterise the metabolites present in human tear fluid using LC-
MS/MS. 
2. To identify the perturbed metabolites and pathways in an in vitro model of 
dry eye disease 
3. To identify the circulating metabolites associated with diabetic 
retinopathy. 
4. To evaluate the performance of SWATH-MS  for metabolite quantitation. 
 
1.3.2. Expanding the Known Metabolic Space of Tear Fluid 
The tear film is an accessible biological fluid to study disorders of the ocular 
surface (26). While the tear proteome (27-31) and lipidome (32, 33) have been 
extensively studied using global proteomic and lipidomic analyses, current 
knowledge of the tear metabolome is limited to a small number of compounds (25, 
34-46). As comprehensive metabonomic profiling has not been performed on tear 
fluid, the first chapter in this thesis addresses this gap developing untargeted LC-
MS/MS methods to identify metabolites present in human tear fluid. 
Complementary column chemistries and ionisation polarities were explored to 
increase the coverage of metabolites identified. 
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1.3.3. Identifying Metabolic Perturbations in an In Vitro 
Model of Dry Eye 
Dry eye disease is a multifactorial disease of the tear film and ocular surface. It is 
characterised by symptoms of discomfort, disturbance in vision and instability of 
the tear film. There are two mechanistic subtypes of dry eye disease – aqueous 
deficient dry eye and evaporative dry eye, and they are known to coexist (47). In 
particular for evaporative dry eye, tear hyperosmolarity as a metabolic stress, has 
a role in developing ocular surface inflammation and cell damage (47).  
 
Several in vitro studies have investigated the mechanisms associated with 
hyperosmolarity-induced cell death of ocular surface cells (48-53) by profiling 
mRNA transcripts or proteins using targeted approaches. Considerably less 
information is known on the regulation of metabolites in ocular surface cells when 
exposed to hyperosmotic stress (54). Galbis-Estrada et al. had identified a few dry 
eye-correlated metabolites in tear fluid, but their findings were limited to highly 
abundant metabolites that could be detected using 1H-NMR (18, 19). Futhermore, 
the observation that choline levels were elevated in patients with dry eye (18) 
conflicts with a later report from the authors that choline levels increased after 
antioxidant supplementation and that this increase in choline levels is associated 
with a decrease in dry eye symptoms (19). 
 
 Studying an in vitro model of dry eye using a more sensitive technique, such as LC-
MS/MS may uncover novel information on less abundant metabolites affected in 
dry eye disease. In the second chapter of this thesis, lysates of human conjunctival 
cells cultured hyperosmotic media were analysed by LC-MS/MS. Proteomic 
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analysis were also performed on the cell lysates to identify correlated with dry eye 
disease.  
 
1.3.4. Investigating Metabolites Correlated With Diabetic 
Retinopathy 
Diabetic retinopathy (DR) is the most common microvascular complication of 
diabetes and the leading cause of visual impairment in working-age adults 
worldwide (55, 56). The disease is characterised by retinal haemorrhage, 
aneurysms, neo-vascularisation of the retina. In an early study using 1H-NMR, 
Barba et al. reported decreased vitreous humour concentrations of galactitol and 
ascorbic acid as metabolic signatures of DR (21). The ideal control group for a 
nested case-control study on DR are diabetic patients with no signs of DR. 
However, the controls in Barba et al.’s were selected from patients undergoing 
vitrectomy for macula hole. This selection of the control group was likely limited to 
the invasive nature of vitreous humour sampling. The obstacles faced in collecting 
vitreous humour samples limits study replication and the translational potential of 
any biomarkers identified from vitreous fluid. Recent metabonomic studies have 
uncovered plasma and sera metabolic signatures associated with, or predictive of 
impaired glucose tolerance and diabetes (57-66). The lack of clear genetic 
associations for DR (67) suggest that that metabotyping at the metabolite level 
might be more suitable for identifying biomarkers of the disease. 
 
When the work in this part of the thesis was being planned,  Li et al. (22) published 
a paper showing that the classification of disease severity in DR patients based on 
metabonomic analysis of plasma metabolites overlapped with the classifications 
based on traditional chinese medicine. There are several limitations to Li et al.’s 
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study. Firstly, the DR patients in their study had high levels of serum creatinine 
than the control group, indicating potentially confounding kidney disease, but this 
was not controlled for in data analysis. Secondly, the fold-changes of their 
identified marker metabolites (besides glucose) were small and identified only 
through orthogonal signal correction-partial least squares-discriminant analysis 
(OSC-PLS-DA) without univariate tests. 
 
In the third chapter of this thesis, plasma metabotypes of DR were investigated 
using GC-MS with samples from the Singapore Indian Eye Study (68). The 
Singapore Indian Eye Study is a well-characterised cohort; clinical data such as 
body mass index (BMI), total cholesterol, low density lipoprotein (LDL) cholesterol 
and high density lipoprotein (HDL) cholesterol, glycosylated haemoglobin (HbA1c), 
and blood pressure (BP) were measured using standardised protocols. DR was 
graded from retinal photographs using a scale modified from the Airlie House 
classification system. Unsupervised principal component analysis (PCA) was 
performed to investigate confounding variable-based clustering. Logistic regression 
was performed on identified metabolite markers of DR to adjust for clinical 
variables. 
 
1.3.5. Applying SWATHTM MS for Metabolite Quantitation 
SWATHTM (Sequential Window of All Theoretical Fragment Ion Spectra) MS is a new 
data acquisition method (69) that offers multiple reaction monitoring (MRM) -like 
quantitation without the need to specify target parent and fragment ions during 
data acquisition. Thus, SWATHTM MS provides superior coverage over MRM by 
capturing all detectable ions in a sample.  Compounds of interest are quantified by 
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extracting high resolution-acquired product ions from the respective SWATHTM 
windows. 
 
While SWATHTM MS is increasingly adopted in quantitative proteomic analysis (70-
74), there are limited reports on applications of SWATHTM MS for the analysis of 
small molecule metabolites. There is only one publication each on utilising 
SWATHTM for toxicological drug screening (75) and identification of drug 
metabolites (76) respectively. As for endogenous metabolites, Siegel et al. had 
developed SWATHTM MS for the quantitation of p-toluenesulfonylhydrazine 
derivatised aldehydes and ketones (77). This chemoselective derivatising agent 
produced a signature fragment ion that distinguished metabolites with aldehyde or 
ketone functional groups from other structures with identical molecular formula. 
 
This chapter of the thesis investigated SWATHTM MS for the quantitation of 
underivatised endogenous metabolites, including low molecular weight such as 
betaine (molar mass: 117.15) and sarcosine (molar mass:  89.09) and metabolites 
with different functional groups. 
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2. Characterisation of The Human Tear Metabolome 
 
2.1. Introduction to The Tear Film 
 
The tear film is a thin layer of fluid contained between the eyelids, covering the 
anterior surface of the eyeball. It is also the extracellular fluid that bathes the 
epithelial cells forming the ocular surface. The tear film provides lubrication, 
protection and nutrition to the ocular surface (78) and its stability is critical for the 
optical quality of the eye (79). There are three main layers of the tear film: 
aqueous, lipid and mucin (78, 80). The aqueous layer is the largest in volume and 
contains dissolved electrolytes, proteins and metabolites. 
 
The tear film is an accessible biological source in studying ocular surface disorders 
as it is directly associated with the corneal surface. The collection of tears is also a 
non-invasive procedure that facilitates large-scale clinical studies. The global 
profiling of tear metabolites is of particular interest as metabonomics provides a 
top-down insight into the dynamic biochemical processes occurring in a biological 
system (81). A characterisation of the human tear metabolome is essential before 
the diagnostic potential of the tear film can be exploited.  
 
While global-omics platforms have been applied to study the tear proteome (27-
31) and lipidome (32, 33) , analysis of the tear metabolome has only been limited 
to targeted metabolite classes (25, 34-46). The number of metabolites identified in 
tears prior to this study was significantly lower compared with the metabolic space 
derived from other biological fluids, such as serum (82) and cerebrospinal fluid 
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(83). A list of metabolites identified in tear fluid prior to this study is shown in 
Table 2.1. 
 
NMR spectroscopy and GC-MS were utilised in the characterisation of less-studied 
metabolomes of saliva (84), amniotic fluid (85) and cerebrospinal fluid (83), these 
platforms were not sufficiently sensitive for the analysis of tear samples. 
 
Prior to the introduction of qradrupole-time-of-flight (Q-TOF) instruments with 
faster duty cycles, the typical workflow in untargeted LC-MS metabonomic analysis 
took on a ‘sniper’ approach. Only high resolution and accurate TOF-MS would be 
acquired in the initial profiling experiments (86). Following peak detection and RT 
alignment, chemometric analysis would be performed to determine differentiating 
peaks (87), out of which only a fraction can be assigned to be metabolite markers. 
Metabolites could be putatively identified by performing targeted fragmentation 
on re-injected samples and comparing the MS/MS spectra obtained with entries in 
databases and then confirmed by analysing pure standards and comparing their 
RTs and fragmentation patterns (88). Such downstream data-processing is time-
consuming and constitutes the largest bottleneck in a metabonomics workflow. By 
contrast, data acquisition in untargeted LC-MS-based proteomic analyses are often 
performed in a shotgun manner (89), with qualitative data acquired 
simultaneously via IDA. This is enabled by the non-redundant nature of peptide 
ionisation and the selection of only multiply-charged species for fragmentation. In 
addition, the use of nano-LC in proteomics further reduces the demands of 
sensitivity and duty cycle on the instrument. 
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Table 2.1 Tear metabolites reported in literature thus far. 
Metabolite Reference Metabolite Reference 
Alkanes and Alkenes  Carnitines  
Squalene (34) Acetylcarnitine  (41) 
  Carnitine (41) 
Amino Acids  Propionylcarnitine (41) 
Alanine (90)   
Arginine (90) Catecholamines and 
 derivatives 
 
Aspartic acid (90) 
Asparagine (90) Epinephrine (42) 
Citrulline (90) Norepinephrine (42) 
Cysteine (35, 36, 90)   
Glutamic acid (90) Hydroxy acids  
Glutamine (90) Ascorbic acid (35, 36) 
Glycine (90) Lactate (37) 
Histidine (90)   
Isoleucine (90) Keto-acids  
Leucine (90) Pyruvate (37) 
Lysine (90)   
Methionine (90) Nucleotides  
Ornithine (90) Diadenosine triphosphate (44) 








Threonine (90)   
Tryptophan (90) Peptides  
Tyrosine  (35, 36, 90) Glutathione (35, 36) 
Valine (90)   
  Purines and derivatives  
Amino Ketones  Uric acid (35, 36, 45) 
Urea (37, 38)   
  Retinoids  
Azoles  Retinol (46) 
Histamine (43)   
  Steroids and derivatives  
Carbohydrates  Cholesterol (34) 
Glucose  (37, 39, 40)   
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This chapter of the thesis developed information-dependent acquisition (IDA) LC-
MS/MS methods to analyse the human tear metabolome and identified 
metabolites through isotope pattern-matched peak mining. 
 
2.2. Methods in Analysis of Human Tear Fluid 
 
2.2.1. Tear Fluid Sample Collection and Preparation 
Tears were collected from six healthy volunteers using Schirmer strips without 
local anaesthesia. All participants had neither ocular complaints nor a history of 
contact lens use. Written consent was obtained from each participant, and the 
study was approved by the SingHealth Institutional Review Board (CIRB 
#2009/910/A). One tear sample was collected from each of the first five 
volunteers. The sixth volunteer was an in-house participant and twelve tear 
samples were collected from this participant over a period of 2 weeks between 9 
am to noon, with no more than one tear sample collected per eye per day. Tear 
samples were stored at −80 °C prior to extraction. Metabolites were extracted 
from the Schirmer strips by vortex-mixing (1200 rpm) each strip in 400 μL of 9:1 
methanol/water for 15 min. Each tear extract from the first five volunteers was 
centrifuged for 10 min at 15,000 g and dried in a vacuum concentrator. Dried 
samples from the first five volunteers were each reconstituted in 30 μL of water. 
Tear extracts from the last volunteer were combined into two pools of six extracts 
each, and dried in a vacuum concentrator. Dried samples from pool 1 and 2 were 
reconstituted in 50 μL of water and acetonitrile (ACN) respectively after drying. 
Schirmer strips with no tears were subjected to the same extraction protocol to 
serve as blank controls. 
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2.2.2. IDA LC-MS/MS 
Chromatographic separation was performed on a Prominence UFLC system 
(Shimadzu, Kyoto, Japan). The autosampler and column heater temperatures were 
maintained at 10 and 40 °C, respectively. The injection volume was 10 μL for all 
analyses. The fraction of pooled tear samples injected was equivalent to the 
volume of a single tear sample. 
 
Samples from the first five participants and pool 1 were injected onto a T3 C18 2.1 × 
100 mm, 3 μm reverse-phase (RP) column (Waters Corporation, Milford, MA, 
USA.). The mobile phase was A: 0.1% formic acid (FA) in water and B: 0.1% FA in 
ACN. The linear gradient profile was 2% B from 0 to 2 min, 15% B at 6 min, 50% B 
at 12 min, 95% B from 16 to 18.5 min, and 2% B from 19 to 25 min. The 
reconstituted sample from pool 2 was injected onto a ZIC hydrophilic interaction 
chromatography (HILIC) 2.1 × 100 mm, 3.5 μm column (Merck SeQuant, 
Darmstadt, Germany). The mobile phase was A: 2 mM ammonium formate in 
water (pH 6.6) and B: 9:1 ACN: 2 mM aqueous ammonium formate (pH 6.6). The 
linear gradient profile was 90% B at 0 min to 80% B at 8 min, 10% B from 15 to 18 
min, and 90% B from 19 to 24 min. The flow rate for all chromatographic methods 
was 0.3 mL/min.  
 
Each sample was analysed in positive and negative ionisation polarities using a 
TripleTOF 5600 Q-TOF mass spectrometer fitted with a DuoSpray ion source (AB 
Sciex, Concord, Canada). Column effluent was directed to the ESI source. The 
source voltage was set to 5.0 kV for positive ionisation and 4.0 kV for negative 
ionisation polarities. The declustering potential (DP) was 80 V and source 
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temperature was 550 °C for both polarities. The curtain, nebuliser and heater gas 
flows were set to 25, 45 and 55 units. 
 
Acquisition of MS/MS spectra was controlled by the IDA function of Analyst TF 
software (AB Sciex). One time-of-flight (TOF) MS survey scan (150 ms) was 
followed by twenty MS/MS scans (50 ms each) with a total duty cycle time of 1.2 s. 
The mass range in both TOF and MS/MS scans was m/z 50–1000. The following 
parameters were applied: (i) dynamic background subtraction, (ii) charge 
monitoring to exclude multiply-charged ions and isotopes, and (iii) dynamic 
exclusion of former target ions for 5 s. Rolling collision energy (CE) was selected, 
whereby CE applied was calculated as a function of m/z by Analyst TF. Mass 
accuracy was maintained by the use of an automated calibrant delivery system (AB 
Sciex) interfaced to the second inlet of the DuoSpray source. Calibrations were 
performed at the start of a workday or whenever ionisation polarity was changed. 
The four combinations of column chemistry and ESI polarities are henceforth 
termed RP (+), RP (−), HILIC (+) and HILIC (−). 
 
2.2.3. Peak Alignment and Multivariate Analysis 
MarkerView (AB Sciex) was used to generate m/z and retention time (RT) peak lists 
from the data files of the first five participants analysed with RP (+) and RP (−) 
analyses. The following parameters were used for peak detection: (i) noise 
threshold of 20 counts, (ii) minimum chromatographic peak width of 3 scans, (iii) 
minimum spectra width of 10 mDa, (iv) background subtraction offset of 5 scans 
and (v) subtraction multiplication factor of 1.2. The peak lists were aligned with the 
following parameters: RT window of 0.7 to 13 min, RT tolerance of 0.3 min, mass 
tolerance of 10 ppm, presence of peaks in at least 4 samples and maximum 
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number of m/z-RT peaks at 50000. PCA of aligned peak data was performed using 
SIMCA (Umetrics AB, Umeå, Sweden) with Pareto scaling. 
 
2.2.4. Isotope Pattern-Matched Peak Mining  
Isotope pattern-matched peak mining was performed on pooled tear samples 
analysed with RP (+), RP (−), HILIC (+) and HILIC (−) using the Extracted Ion 
Chromatogram (XIC) manager add-on for PeakView (AB Sciex). A summary of the 
metabolite identification workflow is given in Figure 2.1. 
 
From a list of metabolites derived from the HMDB (15) (2884 entries, MW from 
100 to 800), the accurate masses of monoisotopic [M+H]+ and [M−H]− ions were 
calculated. The list of [M+H]+  extraction masses was used to extract peaks from 
the RP (+) and HILIC (+)  data files, while the list of [M−H]− ions was used to extract 
peaks from RP (−) and HILIC (−) data files. The search window was set to 0 to 10 
min and 1 to 21 min for RP and HILIC analyses respectively. Peak detection 
parameters were set at (i) intensity count over 200, (ii) signal-to-noise ratio (S/N) 
greater than three and (iii) isotope pattern matching score of 80% and greater.  
 
Entries with peak area values less than 1000 units were removed from the results 
list. The remaining entries were used to extract peaks from the data files of the 
blank controls, with the following modifications: (i) adjustment of the search 
window for each metabolite to ±1 min of their respective retention time as 
detected in the pooled tear samples, and (ii) deactivation of isotope pattern 
matching. Entries with peak area values in the pooled tear samples present at less 




Figure 2.1 Schematic of the IDA-directed LC-MS/MS and isotope pattern-matched 
peak mining workflow. 
 
Selected ion chromatograms were extracted for each m/z in the resultant data 
table to further screen for isobaric ions at other RTs, as the XIC manager reports 
only the peak of greatest intensity across the search window. MS/MS spectra of all 
putative identifications were retrieved from the data files and matched with 
entries in the METLIN (91), MassBank (92) and HMDB (15) mass spectra databases. 
Efforts were made to distinguish metabolites from other isobaric compounds 
whenever possible by virtue of differences in fragmentation pattern. Entries with 
no experimental MS/MS spectra or corresponding spectra in the databases were 
not further identified.  
 
Adenosine diphosphate, allantoin, arginine, carnitine, citric acid, glutamine, 
panthenol, tyrosine, tryptophan, uric acid and xanthine were verified by analysing 
pure standards with the same LC-MS/MS conditions. Standards were purchased 
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2.3. Results and Discussion: Identification of Tear 
Metabolites 
 
2.3.1. Resolution of Metabolite Signals from Collection 
Matrix 
The PCA scores plot of tear samples from the first five volunteers and blank 
controls (collection matrix) derived from RP (+) and RP (−) analyses are shown in 
Figure 2.2. Both models were optimised at two principal components (PCs) with R2 
values of 0.91. The Q2 values of the RP (+) and RP (−) models were 0.73 and 0.81 
respectively. In both models, tear samples were separated from the blank controls 
along the first PC. The first PC accounted for 82% of model variation in RP (+) and 




Figure 2.2 PCA scores plot of tear samples (blue circles, n =5) and blank controls 
(red triangles, n=5) obtained from analysis in A) positive ionisation polarity and 





2.3.2. Workings of XIC Manager 
Unlike typical data processing in metabonomic analysis where data are subjected 
to peak detection and experimental masses are obtained, this workflow operates 
in a reverse manner whereby theoretical masses from the in-house library are used 
to extract isotope pattern-matched peaks from experimental data. Although a 
recent publication reported the use of similar software for drug screening in 
conjunction with targeted analysis (93), there is no precedence of isotope pattern-
matched peak mining in global metabonomic analysis. 
 
Representative features of XIC Manager are shown in Figure 2.3, with the 
identification of xanthine as an example. Figure 2.3A shows the output of XIC 
manager after isotope pattern-matched peak mining was performed on the RP (+) 
data file. The green circles indicate that the errors in mass and isotope pattern 
were less than 10 ppm and 20% respectively (user-set thresholds). In addition to an 
output table, XIC manager extracts ion chromatograms of all putative metabolites. 
The XIC of xanthine (RT of 2.05 min on RP) is highlighted in Figure 1.3B. The TOF-
MS and MS/MS spectra of xanthine are shown in Figure 1.4A and Figure 1.4B 






Figure 2.3 A) Output of XIC Manager for RP (+) analysis and B) XIC of xanthine 








Figure 2.4 A) TOF-MS spectrum of xanthine and B) MS/MS spectrum of Xanthine 












2.3.3. Identified Tear Metabolites 
Using isotope pattern-matched peak mining, 60 metabolites were identified in 
human tears (Table 2.2). This study reports the presence of 44 of these 
metabolites in human tear fluid for the first time (Table 2.2) A diverse range of 
compound classes are represented (amino acids, carnitines, nucleotides, 
phospholipids etc.), thereby demonstrating good coverage of the analytical 
method. The RTs of metabolites found in each analytical mode are given in Table 
2.3. Metabolites were reported together as a single entry when resolution of 
isobaric compounds was not possible. For example, fumaric acid and maleic acid, 
the trans and cis isomers of butenedioic acid produce identical MS/MS fragments 
and were not resolved with the chromatography method used in this study.  
Fumaric acid is a key intermediate in the citric acid cycle and is thus expected to be 
present in tear fluid. While maleic acid is not an intermediate in major metabolic 
pathway, it is found in human urine (94) and thus cannot be excluded from being 
present in tear fluid. 
 
Metabolites that covered a range of chemical structures, polarities and isotope 
distribution patterns were selected for confirmation. They were adenosine 
diphosphate, allantoin, arginine, carnitine, citric acid, glutamine, tyrosine, 
tryptophan, panthenol, uric acid and xanthine. 
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Table 2.2 Metabolites detected in tears by IDA LC-MS/MS peak mining. 
Amino Acids Carbohydrates Nucleotides 
1-Methylhistidine/ 
3-Methylhistidine 
N-Acetylneuraminic acid Guanosine 
monophosphate  





Acetylcarnitine c  Uridine diphosphate 





Palmitoylcarnitine c  
Citrulline a   
Creatine Cyclic Amines 
Glutamic acid a Niacinamide   
Glutamine a, *  Peptides 
Homoarginine Dicarboxylic Acids Oxidised glutathione 
Hydroxyproline Fumaric acid/ 
Maleic acid  
 
Phenylalanine a   Phospholipids 
Proline a   1-Palmitoyl- 
lysophosphatidylcholine Pyroglutamic acid Nucleosides 
Serine a  1-Methyladenosine  
Taurine a  Adenosine Purines and derivatives 
Threonine a Cytidine Hypoxanthine 
Tyrosine b, *  Guanosine Theobromine 




Valine a   
 S-Adenosyl-methionine Pyridoxals and 
derivatives Amino Alcohols Uridine 
Panthenol* Xanthosine 4-Pyridoxic acid 
   
Amino Ketones Nucleotides Quaternary Amines 





Aromatic Acids Cytidine monophosphate  









a reported in (90)  
b reported in (35, 36, 90)  
c reported in (41) 
d reported in (35, 36, 45) 






Table 2.3 Formulae, monoisotopic masses and RTs of metabolites identified using multiple analytical modes. 
# Formula Mass (m/z) Name 
RT (min) 
RP (+) RP (−) HILIC (+) HILIC (−) 
1 C11H15N5O4 281.1124 1-Methyladenosine 1.67 




  10.80  
2b 3-Methylhistidinea 
   
















7 C10H13N5O4 267.0968 Adenosine 3.29 3.13 1.42 1.41 
8a 






8b Symmetric dimethylarginineb 
   




10 C4H6N4O3 158.0440 Allantoinc,* 
   
2.43 
11 C10H14N5O7P 347.0631 Adenosine monophosphate 1.55 1.60 3.70 3.68 








14 C9H8O2 148.0524 Cinnamic acid 
   
2.01 












        





# Formula Mass (m/z) Name 
RT (min) 








18b m-Coumaric acida 
  
18c p-Coumaric acida 
  




20 C4H7N3O 113.0589 Creatinine 
   
1.78 
21 C9H13N3O5 244.0935 Cytidine 1.51 
   










23b Maleic acida 
    
24 C5H9NO4 147.0532 Glutamic acid 
  
5.56 5.42 
25 C5H10N2O3 146.0691 Glutamine* 
 
1.03 5.69 5.66 




27 C10H14N5O8P 363.0580 Guanosine monophosphate 1.65 1.73 
  
28 C10H13N5O6 284.0917 Guanosine 3.79 3.76 2.35 2.35 








31 C5H9NO3 131.0582 Hydroxyproline 
  
4.64 4.63 
32 C5H4N4O 136.0385 Hypoxanthine 1.80 1.80 1.55 
 
33 C10H13N4O8P 348.0471 Inosine monophosphate 1.70 1.80 
  
34 C10H12N4O5 268.0808 Inosine 3.79 3.76 1.84 1.83 
35 C11H19NO9 309.1060 N-Acetylneuraminic acid 
   
4.58 
36 C6H6N2O 122.0480 Niacinamide 1.65 






# Formula Mass (m/z) Name 
RT (min) 
RP (+) RP (−) HILIC (+) HILIC (−) 
37 C20H32N6O12S2 612.1520 Oxidised glutathione 2.15 2.29 
  




39 C9H19NO4 205.1314 Panthenol* 5.66 5.69 1.18 
 
40 C9H11NO2 165.0790 Phenylalanine 4.37 4.35 2.01 
 
41 C5H14NO4P 183.0661 Phosphocholine 1.04 
   
42 C5H9NO2 115.0633 Proline 
   
3.80 




44 C14H20N6O5S 384.1216 S-Adenosyl-homocysteine 2.17 
   




46 C3H7NO3 105.0426 Serine 
  
6.01 5.98 
47 C2H7NO3S 125.0147 Taurine 
 
0.98 4.56 4.56 
48 C7H8N4O3 181.0647 Theobromine 5.98 
   
49 C4H9NO3 119.0582 Threonine 
   
4.76 
50 C11H12N2O2 204.0899 Tryptophan* 6.65 6.68 2.28 2.28 
51 C9H11NO3 181.0739 Tyrosine* 2.15 2.22 
 
3.24 









54 C5H4N4O3 168.0283 Uric acid* 1.72 1.78 3.12 2.94 






  6.26  
56b UDP-N-acetylglucosaminea 
   





# Formula Mass (m/z) Name 
RT (min) 
RP (+) RP (−) HILIC (+) HILIC (−) 




59 C5H4N4O2 152.0334 Xanthine* 2.05 2.17 
 
1.51 




a chromatographically and spectrally unresolvable 
b partially resolved by chromatography, spectrally unresolvable 
c identified through manual search 
* verified with standard 
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2.3.4. Evaluation of Workflow 
In this study, entries with peak intensities in tear samples that were less than five 
times the levels in blank controls were removed. This filter significantly reduced 
the likelihood of mis-identifying artefacts leeched from Schirmer strips as 
endogenous tear metabolites. These results show that the LC-MS/MS platform is 
sufficiently sensitive in detecting endogenous metabolites from the small volume 
of tears in the presence of matrix components. 
 
Coverage of the tear metabolome was increased by the utilisation of 
complementary column chemistries and ionisation in both positive and negative 
polarities. The sole use of RP (+), RP (−), HILIC (+), or HILIC (−) would result in the 
identification of only 26, 25, 35 or 22 metabolites respectively (Table 2.3). While 
HILIC is accepted to be complementary to RP in selectivity, (95) a total reversal in 
the elution order of metabolites should not be expected. For example, 
hypoxanthine eluted before inosine on both RP and HILIC columns in our study and 
this elution pattern has also been reported in literature (96, 97). The HILIC particle 
is zwitterionic, thus its selectivity and retention are influenced by pH and ionic 
strength to a greater extent than RP.  
 
The acquisition of both TOF-MS and MS/MS spectra in a single data file was made 
possible by utilising a short duty cycle with a high number of product ion scans (20 
MS/MS scans in a cycle time of 1.2 s). This facilitated the mass resolution of co-
eluting metabolites and increased the chances of [M+H]+/[M−H]− species being 
selected for fragmentation amongst redundant signals. In addition, exclusion of 
former selected target ions in IDA parameters improved the instrument’s 
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productivity in acquiring non-repeated MS/MS spectra by selecting new-eluting 
metabolite signals for fragmentation. 
 
Mass accuracy and high mass resolution form the foundation of this peak mining 
workflow. These parameters were measured to be 6 ppm (average 2.4 ppm from 
all identified metabolites) and over 30,000 at m/z 400 respectively (Figure 2.5). The 
use of an orthogonal isotope pattern filter greatly reduced the probability of 
detecting background noise and redundant signals as monoisotopic peaks, and 
eliminated false positives from compounds with similar molecular weights (98).  
 
Several challenges were encountered during metabolite identification: i) 
metabolites with identical molecular formulae, ii) in-source fragmentation and iii) 
adduct formation and these are illustrated henceforth. In the first example, a peak 
with m/z 282.083 was detected at 3.76 min on RP (+), with guanosine or 8-
hydroxy-deoxyguanosine being possible identifications. By comparing the 
experimentally-derived MS/MS spectra of this peak to MS/MS spectra of 
guanosine and 8-hydroxydeoxyguanosine entries in METLIN (91), the peak was 




Figure 2.5 TOF-MS spectrum of palmitoylcarnitine. 
 
 
In the case of in-source fragmentation, inosine (m/z 269.088) and hypoxanthine 
(m/z 137.046) were both putatively identified in XIC manager at the same 
retention time of 3.79 min on RP (+), with their MS/MS spectra matching the 
respective entries in METLIN (91) and MassBank (92). Inosine has been reported to 
fragment at source to form hypoxanthine (99) should elute at a later RT than 
hypoxanthine. Extraction of m/z 137.046 across the whole chromatogram showed 
another peak at 1.80 min. This peak at 1.80 min was identified to be hypoxanthine 
based on its MS/MS spectra. In the last example, N-succinyl-2-amino-6-
ketopimelate (m/z 290.087) was putatively identified at 3.29 min but a query of 
the compound on HMDB (15) and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) (100) showed that N-succinyl-2-amino-6-ketopimelate is not involved in 
primary metabolism in humans. As this ion of m/z 290.087 showed identical 
retention with adenosine and a difference of 22.990 Da from the monoisotopic 
mass, this peak was identified as the sodium adduct of adenosine. 
Peak width at half 
maximum = 0.0122 Da
Mass resolution = 32,768
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The efficiency of isotope pattern-matched peak mining was evaluated using the 
subset metabolite candidates with molecular weight between 100 to 300 data 
searched on the RP (+) data file (Table 2.4). After removing entries with no MS/MS 
spectra and duplicate m/z values, 36 unique extraction masses remained. Out of 
these, 20 metabolites were identified, and 3 entries failed to match with database 
spectra. Five entries were found to be adducts or product ions from in-source 
fragmentation (n = 5) of other metabolites. Eight entries could not be identified as 
there were no mass spectra of these candidates in databases. Thus, the false 
discovery rate the isotope pattern-matched peak mining workflow prior to MS/MS 
identification is less than 10% (3 out of 36).  
 
The accuracy of isotope abundances is influenced by several factors such as ion 
intensity, relative abundance of isotope peak and competitive ionisation (101). This 
workflow was based on the presumption that at least the M+1 isotope of each 
metabolite was detectable on the Q-TOF instrument, and the intensity of the 
respective isotopes were within 80% accuracy of calculated isotope distributions. 
 
Given these limitations, the list of identified metabolites presented in Table 2.2 is 
by no means exhaustive as metabolites displaying the following attributes would 
possibly remain unreported: (i) strong adduct formation with sodium or formate 
ions, (ii) present at a low concentration in tear samples, and (iii) low molecular 
weight with a small number of carbon atoms. For example, allantoin (C4H6N4O3) 
was only identified upon further investigation. It was initially unreported by XIC 
manager as the M+1 isotope peak (calculated relative abundance of 5% to the 
monoisotopic peak) was below the detection limit of the mass spectrometer. 
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Table 2.4 Evaluation of workflow using subset of metabolite candidates with 
molecular weight from 100 to 300 searched on RP (+) 
Metabolite assignment 
Number of metabolite 
candidates 
Starting entries 109 
Entries with no MS/MS spectra 13 
Duplicate m/z 59 
Putative identifications  36 
Identified metabolites 20 
No match to database entries 3 
Adducts and fragments 5 
No spectra in databases 8 
 
 
2.4. Summary for Characterisation of The Human Tear 
Metabolome 
 
Isotope pattern-matched peak mining enabled the identification of 60 metabolites 
in human tear fluid. These metabolites encompass a wide range of compound 
classes, and 44 were identified for the first time in tear samples. The separation of 
tear samples from Schirmer strip blanks by PCA shows that the LC-MS/MS 
analytical platform is sufficiently sensitive for global metabonomic profiling of tear 




3. Metabonomic and Proteomic Analysis of an In Vitro 
Model of Dry Eye Disease 
 
3.1. Introduction to Dry Eye Disease 
 
Dry eye disease is a multifactorial disease of the tear film and ocular surface. It is 
characterised by symptoms of discomfort, disturbance in vision and instability of 
the tear film. There are two mechanistic subtypes of dry eye disease – aqueous 
deficient dry eye and evaporative dry eye, and they are known to coexist (47). In 
particular for evaporative dry eye, tear hyperosmolarity as a metabolic stress, has 
a role in developing ocular surface inflammation and cell damage (47). The 
prevalence of dry eye is high and estimated to be between 11 to 17% among 
persons over 40 years old in predominantly-Caucasian populations (102-104) and 
between 21 to 33% in Asian populations (105-107). The prevalence of dry eye 
disease increases with age and is higher in females (102). 
 
The disparity in global prevalence rates could be attributed to the use of different 
diagnostic criteria, with individual clinical signs demonstrating poor agreement 
with disease severity (108). A combination of clinical assessments such as 
self-reported symptoms, corneal and conjunctiva staining, tear break up time, tear 
volume by Schirmer’s test and meibomian gland function are used for the 
diagnosis of dry eye disease and response to treatment (47). While the 
combination of such methods yields improved sensitivity and specificity (109), 
diagnosis remains time- and resource-consuming, and highly dependent on the  
judgement of trained physicians (108). The lack of objective assessment of 
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treatment outcomes hinders agreement among clinicians and also the 
development of targeted pharmacotherapies. Artificial tear formulations are 
available over-the-counter but they merely provide symptomatic relief. In view of 
the gaps in clinical knowledge, current research efforts in dry eye disease are 
directed towards (i) selective biomarker discovery and (ii) elucidation of disease 
mechanism in animal and cell models. Several studies have been conducted to 
identify biomarkers of dry eye disease using proteomic approaches (27, 110, 111), 
including subsets of mild dry eye (110) and contact lens-related dry eye (111).  
 
Hyperosmolarity is known to exert pleiotropic effects on cellular function on 
mammalian renal cells (112), including cell cycle arrest and increased apoptosis 
(113). Several in vitro studies have been performed to investigate the mechanisms 
associated with hyperosmolarity-induced cell death of ocular surface cells. Li et al. 
were the first to demonstrate the involvement of mitogen-activated protein kinase 
(MAPK) signalling pathway (48). Subsequent studies have shown that c-Jun 
N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) pathways 
(49) induce apoptosis in human corneal epithelial through a cytochrome c-
mediated pathway (50) dependent on transglutaminase (52). Collectively, these in 
vitro mechanistic studies confirmed the involvement of cellular signalling pathways 
in hyperosmolarity-induced cell death and suggested the potential dysregulation of 
signalling pathways and endogenous metabolites in dry eye disease. 
 
Most published work have focused on profiling mRNA transcripts or proteins using 
targeted approaches (48-53). Considerably less information is available on the 
regulation of metabolites in ocular surface cells when exposed to osmotic stress 
(54). We postulate that global non-targeted profiling of the metabolome and 
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proteome could reveal novel and complementary information on pathways 
affected in dry eye disease. This chapter of the thesis investigated the 
perturbations in a cell model of dry eye using global metabonomic and proteomic 
analyses.   
 
3.2. Methods in Analysis of Cell Lysates 
 
3.2.1. Cell Line and Cell Culture 
The non-transfected, spontaneously immortalised normal human conjunctival 
epithelial (IOBA-NHC) cell line was a gift from Dr. Yolanda Diebold at the University 
of Valladolid, Spain (114). Cells were maintained in a modified medium consisting 
of 1:1 mixture of Dulbecco's Modified Eagle Medium/Ham’s F-12 culture media 
(Invitrogen, Carlsbad, CA, USA.) with 10% fetal bovine serum (Invitrogen), 2 ng/mL 
of recombinant human epidermal growth factor (Invitrogen), 1 μg/mL of bovine 
insulin (Sigma Aldrich), 0.1 μg/mL of cholera toxin, (Sigma Aldrich), 0.5 μg/mL of 
hydrocortisone and 1× strength of broad spectrum antibiotic-antimycotic 
(Invitrogen). Prior to the experiment, cells were subcultured, grown to 80% 
confluence and adapted to Keratinocyte serum-free medium (KSFM) (Invitrogen) 
media overnight.  
 
The cells were further cultured for 24 h in KFSM at 280, 380 and 480 mOsm for the 
control, treatments T1 and T2 respectively. The treatment conditions were 
selected to represent elevated tear osmolarity found in patients with dry eye 
(115). Five biological replicates were prepared for global metabonomic analysis, 
and three biological replicates each were prepared for targeted metabonomics, 
proteomic analysis and Western blot for UDP-N-acetylhexosamine 
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pyrophosphorylase (UAP1) (Figure 3.1). Each hyperosmotic medium was prepared 
by the addition of 2 M sodium chloride prepared in phosphate-buffered saline 
(PBS) to commercial KFSM. Osmolarity measurements were performed using a 
vapour pressure osmometer (Wescor Inc., Logan, UT, USA.). Detailed sample 
preparation methods are provided in the appendices. 
 
3.2.2. Metabonomic Analysis 
Analysis was performed on a Prominence UFLC system (Shimadzu) coupled to an 
TripleTOF 5600 Q-TOF mass spectrometer (AB Sciex). A T3 C18 2.1 × 100 mm, 3 μm 
column (Waters Corporation) was used for separation. Each sample was 
reconstituted in 50 µL of water and 10 µL was injected for each analysis in the 
positive and negative ionisation polarities. The mobile phase for the positive 
ionisation polarity was 0.1% formic acid in water (eluent A) and 0.1% formic acid in 
ACN (eluent B). The linear gradient profile was 2% B from 0 to 2 min, 15% B at 8 
min, 50% B at 14 min, 90% B from 18 to 20.5 min, and 2% B from 21 to 27 min. The 
mobile phase for the negative ionisation polarity was 5 mM ammonium formate 
and 0.05% formic acid in water (eluent A), and 5 mM ammonium formate and 
0.05% formic acid in 9:1 ACN/water (eluent B). The linear gradient profile was 2% B 
from 0 to 2 min, 15% B at 8 min, 50% B at 14 min, 100% B from 18 to 20.5 min, and 





Figure 3.1 Schematic of experiments performed to investigate changes in 
expression of metabolites and proteins in IOBA-NHC cells under different degrees 
of hyperosmotic stress. 
 
 
Acquisition of MS/MS spectra in both ionisation polarities was controlled by the 
IDA function of Analyst TF. One TOF-MS survey scan (150 ms) was followed by 25 
MS/MS scans (50 ms each). The mass range of TOF-MS and MS/MS scans were m/z 
50–1000 and 25–1000 respectively. The source voltage was 5.0 kV for positive 
ionisation and 4.0 kV for negative ionisation polarities respectively. The following 
parameters were applied: dynamic background subtraction, charge monitoring to 
exclude multiply charged ions and isotopes, and dynamic exclusion of former 
target ions for 5 s. CE was ramped from 20–30 V in MS/MS scans. 
 
3.2.3. Peak Finding and Alignment of Metabonomic Data 
MarkerView (AB Sciex) was used for peak detection and alignment of raw 
chromatographic data obtained from the respective positive and negative 
ionisation polarities. Peak detection and alignment parameters are provided in 












peak area of all variables present in analysed samples was generated for each 
ionisation polarity. The following peak classes were excluded from subsequent 
analysis: (i) peaks attributed to isotopes, (ii) peaks with an average area that were 
less than three times the average area in blank injections and (iii) peaks with a 
coefficient of variation (CV) greater than 80% among replicates. The samples in 
each peak table were normalised to their respective 90th percentile peak area 
sums. 
 
3.2.4. Statistical Analysis and Metabolite Identification 
The Kruskal–Wallis test (a non-parametric analysis of variance) was used to identify 
m/z-RT metabolite peaks with statistically significant median peak areas in at least 
one group (control, T1 or T2) when compared with other groups. Subsequently, 
the Mann-Whitney U test was used to identify m/z-RT metabolite peaks with 
integrated peak areas that were significantly different in treatments T1 or T2 as 
compared with control samples. Metabolite fold-changes between treatment and 
control groups were calculated using the arithmetic mean. The m/z value of each 
marker peak was queried in METLIN metabolite database (91) to obtain its putative 
metabolite identification. For this step, the batch search mode was adopted, with 
mass accuracy set to 12 ppm. The following adducts were applied to the m/z 
values of marker peaks obtained via positive ionisation polarity: [M+H]+, [M+NH4]+ 
[M+Na]+, [M+K]+ and [M−H2O+H]+. Similarly, [M−H]−, [M−H2O−H]−, [M+Cl]− and 
[M+FA−H]− were applied to m/z values obtained via the negative ionisation 
polarity. Metabolite were identified by retrieval of experimental MS/MS spectra 
and comparison with the respective entries in METLIN (91) or MassBank (92) mass 
spectra databases. Unresolved metabolites with the same molecular formula were 
reported as mixtures. 
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3.2.5. Targeted Metabonomic Analysis 
The levels of carnitine, glycerophosphocholine and phosphocholine were verified 
in independently-prepared replicates of IOBA-NHC cell lysates. Carnitine, 
glycerophosphocholine and phosphocholine were purchased from Sigma Aldrich. 
Separation was performed on a Prominence UFLC system (Shimadzu) with a ZIC 
HILIC 2.1 × 100 mm, 3.5 μm column (Merck SeQuant). The mobile phase for was 5 
mM ammonium formate and 0.05% formic acid in water (eluent A), and 5 mM 
ammonium formate and 0.05% formic acid in 9:1 ACN/water. The linear gradient 
profile was 80% B at 0 min, 40% B at 8 min, 20% B from 9 to 11 min, and 80% B 
from 11 to 15 min. The flow rate was 0.4 mL/min. MRM was performed on a QTrap 
6500 ion trap mass spectrometer (AB Sciex). The optimised MRM parameters for 
each target compound are shown in Table 8.2 in the appendices. 
 
3.2.6. Proteomic Analysis 
Samples were trypsin-digested with filter-aided sample preparation (FASP) kits 
(Protein Discovery, San Diego, CA, USA.) and labelled with isobaric tags for relative 
and absolute quantification (iTRAQ) reagents (AB Sciex) for proteomic analysis 
(116). In this study, reagent 114 was added to control samples, reagent 115 was 
added to T1 samples and reagent 116 was added to T2 samples. After labelling, 
one control sample, one T1 sample and one T2 sample were pooled together for 
injection onto the LC-MS/MS system. For each peptide sequence, labelled peptides 
from different samples give the same m/z in TOF-MS but produce reporter ions 
with different m/z in MS/MS. Thus, the ratio of signal intensities for m/z 115:114 in 
a MS/MS spectrum of a peptide gives the relative amount of that peptide in 
treatment T1 compared with the control, and the ratio of signal intensities for m/z 
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116:114 gives the relative amount of that peptide in treatment T2 compared with 
the control.  
 
Chromatographic separation of peptides was performed on an Ultimate 3000 
nano-LC system (Dionex, Thermo Scientific, Sunnyvale, CA, USA). Samples were 
first loaded onto a 75 µm × 2 cm Acclaim PepMap 100 C18 trap column (Dionex, 
Thermo Scientific) at a flow rate of 5 µL/min. After a 5 min wash with 0.1% formic 
acid and 2% ACN in water, the trap column was switched to be in-line with a 75 µm 
× 15 cm Acclaim PepMap RSLC C18 analytical column (Dionex, Thermo Scientific). 
The mobile phase was 0.1% formic acid in water (eluent A) and 0.1% formic acid in 
98:2 v/v of ACN/water (eluent B). The linear gradient profile was 5% B at 0 min, 7% 
B at 5 min, 60% B at 97 min, and 95% B from 100 to 105 min. The flow rate was 
300 nL/min. 
 
Data was acquired via the IDA mode using the Analyst TF 1.6 software (AB Sciex). 
The source voltage was 2.5 kV and the DP was 100 V. The interface heater 
temperature was 125 °C. The curtain and nebuliser gas flows were 30 and 12 units 
respectively. The IDA parameters are as follows: 0.25 s of TOF-MS survey scan (m/z 
range: 350–1250) was followed by thirty product ion scans of 75 ms each (m/z 
range: 100–1800). The switching criteria was set to include only ions with charge 
states of 2 to 5, and an abundance threshold of over 100 counts for fragmentation. 




3.2.7. Protein Identification and Data Analysis 
ProteinPilot (AB Sciex, version 4.5) was used to analyse MS/MS data output, and 
MS/MS spectra were searched against the UniProt database (September 2010 
release, 40516 proteins in database). Important settings in ProteinPilot were 
configured as follows:  (i) sample type: iTRAQ 4plex (peptide labelled), (ii) Cys 
alkylation: iodoacetamide, (iii) digestion: trypsin, (iv) instrument: TripleTOF 5600, 
(v) special factors: none, (vi) ID focus: biological modifications, (vii) search effort: 
thorough ID and (viii) application of bias correction and background. 95% 
confidence level was used at the peptide level. False discovery rate (FDR) analysis 
in the ProteinPilot software was performed and FDR < 1% was set for protein 
identification. Reverse database search strategy was used to calculate FDR for 
peptide identification. The Pro Group algorithm in ProteinPilot was used to 
calculate peak areas of reporter ions. Auto bias correction was applied to eliminate 
possible pipetting errors in the combination of labelled samples. 
 
Proteins were considered significantly up-regulated if their log-transformed iTRAQ 
ratios (treatment T1: controls or treatment T2: controls) were above one standard 
deviation (SD) of the global mean in at least two out of three replicates, and if their 
fold-changes were greater than 1.4. Proteins were considered significantly down-
regulated if their iTRAQ ratios were below one SD of the global mean in at least 
two out of three replicates, and if their fold-changes were less than 0.71. The 
average of the global mean iTRAQ ratios obtained in our experiments was 0.99. 
The average of the global SD of log-transformed iTRAQ ratios was 0.15. The 
average upper and lower thresholds were 1.4 and 0.71 respectively. Protein fold-
changes between control and treatment groups were calculated using the 
geometric mean in the normal space. 
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3.2.8. Western Blot for UAP1 
Denaturing electrophoresis was performed on lysates and proteins were 
transferred to nitrocellulose membranes. The membranes were blocked with 5% 
milk in Tris-buffered saline with Tween 20 before incubation with UAP1 antibody 
(1:500) (Sigma Aldrich) for 16 h at 4 °C. Protein bands were visualised by using the 
Supersignal West Pico chemiluminescence kit (Thermo Scientific, Waltham, MA. 
USA). The blot was also probed with β-actin antibody (1:5000) (Sigma Aldrich) to 
function as an internal control. 
 
3.3. Results and Discussion: Markers from In Vitro 
Model of Dry Eye Disease 
 
3.3.1. Metabonomic Analysis 
There were 1940 m/z-RT  features from the positive ionisation polarity and 1386 
m/z-RT features from the negative ionisation polarity. Fifteen dysregulated 
metabolites were identified by the positive ionisation experiments, while eight 
were identified by the negative ionisation experiments (Table 3.1, Figure 3.2). 
Methionine and tyrosine were identified in both the positive and negative 
ionisation polarities. Several of these dysregulated metabolites were previously 
reported in human tear samples (117), making them potential biomarkers of 
conjunctival cell function in dry eye disease. Experimental MS/MS spectra of 
glycerophosphocholine and UDP-N-acetylglucosamine are shown in Figure 3.3 and 
Figure 3.4 respectively. Data files from global metabonomic analysis have been 





Figure 3.2 A) Summary of the numbers of unique and overlapping dysregulated 
metabolites and proteins in IOBA-NHC cells under hyperosmotic stress. B) 













































Treatment T1 Treatment T2
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Table 3.1 Metabolites in IOBA-NHC cells dysregulated by hyperosmotic stress. 
Metabolite Detecte









[M+H]+ 232.155 5.49 1.59‡ 1.24 
Carnitine*,† [M+H]+ 162.113 0.89 1.84‡ 1.70‡ 
Glutamic acid† [M−H]− 146.046 0.93 1.92‡ 1.81‡ 
Glutamine*,† [M−H]− 145.061 0.86 2.16‡ 2.11‡ 
Glutaminyl-Leucine [M+H]+ 260.161 4.76 1.70 2.43‡ 
Glycerophosphocholine*,† [M+H]+ 258.109 0.88 6.00‡ 11.3‡ 
Leucine* [M+H]+ 132.103 2.37 1.31 1.94‡ 
Methionine*,† 
[M−H]− 148.043 1.42 2.04‡ 1.94‡ 
[M+H]+ 150.058 1.42 2.05‡ 2.77‡ 
N-acetylglutamine [M−H] − 187.072 1.04 2.22‡ 2.51‡ 
Niacinamide† [M+H]+ 119.048 2.27 1.60 2.23‡ 
Panthothenic acid* [M−H] − 218.103 5.14 0.74 0.42‡ 
Phenylalanine*,† [M+H]+ 166.086 4.49 1.74 2.10‡ 
Phosphocholine† [M+H]+ 184.074 0.86 1.74‡ 1.17 
Proline [M+H]+ 116.071 0.96 1.49 1.65‡ 
S-Adenosylmethionine† [M+H]+ 399.145 0.85 1.46 1.86‡ 
Tryptophan* [M+H]+ 205.097 6.52 1.58 2.31‡ 
Tyrosine* 
[M−H]− 180.065 1.71 1.79‡ 1.85‡ 
[M+H]+ 182.082 2.29 1.75‡ 2.37‡ 




[M+H]+ 246.171 7.62 1.69 1.89‡ 
Valine*,† [M+H]+ 118.086 1.33 1.55 1.91‡ 
Xanthine*,† [M−H]− 151.026 2.00 1.77 2.02‡ 
* Verified with standard 
† Previously detected in human tear samples 





Figure 3.3 A) MS/MS spectra of glycerophosphocholine derived from 
metabonomic analysis of IOBA-NHC cell lysate and B) verified with standard 
















Figure 3.4 A) MS/MS spectra of UDP-N-acetylglucosamine derived from 
metabonomic analysis of IOBA-NHC cell lysate and B) verified with standard 















3.3.2. Osmoprotectant Metabolites 
Several groups have investigated the effect of small molecule osmoprotectants 
using in vitro and animal models of dry eye. Corrales et al. found that 
supplementation of carnitine or erythritol in culture media reduced the levels of 
activated JNK and p38 MAPK in human corneal epithelial cells under hyperosmotic 
stress (119). Garett et al. found the addition of betaine to culture media reduced 
apoptosis in human corneal limbal epithelial cells (120). More recently, Hua et al. 
foundy that carnitine, betaine and erythritol suppressed the expression of pro-
inflammatory cytokines in human corneal epithelial cells cultured in hyperosmotic 
media (121). Chen et al. established that carnitine, betaine and erythritol reduced 
the expression of pro-inflammatory cytokines in the conjunctiva and reduced 
apoptosis in the corneal tissues in a mouse model of dry eye (122). 
 
In this study, carnitine levels in IOBA-NHC cells were increased under treatments 
T1 and T2, in agreement with its function as an osmoprotectant. In addition, the 
levels of short-chain carnitines were found to be increased under hyperosmotic 
conditions although dose-dependency with increasing osmolarity was not 
observed. While betaine was detected in the positive ionisation polarity (m/z 
118.086, RT 0.88 min) in metabonomic analysis, it did not show any significant 
increase under either hyperosmotic stress treatment (p>0.05). Erythritol was not 
detected in IOBA-NHC cells in our study. Our results show that carnitine is a 
preferred endogenous osmoprotectant over betaine.  
 
Among the dysregulated metabolites identified from global metabonomic analysis, 
glycerophosphocholine showed the largest fold-change and a dose-dependent 
relationship with increasing osmotic stress (Table 3.1, Figure 3.2). An increase in 
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phosphocholine, a key intermediate in glycerophosphocholine synthesis was also 
observed under treatment T1 but not treatment T2 (Figure 3.5). This suggests that 
an overall activation of this pathway under hyperosmotic stress and a depletion of 
intermediates at high osmotic stress. Although glycerophosphocholine is a well-
studied osmolyte in renal medullary cells (123, 124) and has been detected in 
rabbit corneas (16), this study is the first to report its involvement the osmotic 
stress response in ocular surface cells. The dose-dependent elevation in 
glycerophosphocholine levels suggests that it is more readily-accumulated than 
other osmoprotectants in IOBA-NHC cells, and its accumulation is a more sensitive 
response to hyperosmotic stress. 
 
To investigate if glycerophosphocholine is the preferred endogenous osmolyte 
over carnitine, these metabolites from three independent biological replicates 
were quantified using MRM (Figure 3.1). Carnitine levels showed a 1.4 fold 
increase under treatment T1 and 2.1 fold increase under T2 (Table 3.2). 
Glycerophosphocholine showed a 2.1 fold increase under treatment T1 and 5.8 
fold increase under T2 (Table 3.2), showing dose-dependent up-regulation of 
glycerophosphocholine with increasing osmotic stress. Collectively, these results 
suggest that glycerophosphocholine is the preferred endogenous osmolyte in 
IOBA-NHC cells. It would be pertinent to investigate the efficacy of 
glycerophosphocholine in reducing inflammation and apoptosis in in vitro and 




Figure 3.5 A) Synthesis pathway of glycerophosphocholine, CHKA: choline kinase 
alpha, PYCT1: choline-phosphate cytidylyltransferase, CHPT: 
cholinephosphotransferase 1, PLB: phospholipase B1, PLA2: phospholipase A2:, 
LYPLA: lysophospholipase.  B) Relative amount of phosphocholine in control, T1 
and T2 cell lysates. C) Relative amount of glycerophosphocholine in control, T1 




















































Table 3.2 MRM-validated fold-changes of carnitine, glycerophosphocholine and 





Carnitine 1.43 2.13 
Glycerophosphocholine 2.68 5.83 
 
 
3.3.3. Proteomic Analysis 
A total of 2373 proteins were identified from proteomic analyses, with 1483 
common proteins among the three replicates. Only proteins with at least two 
unique peptides were considered for statistical analysis. Compared with controls, 
there were 26 proteins with increased levels and 20 proteins with decreased levels 
under treatment T1 (380 mOsm), and 45 proteins with increased levels and 20 
proteins with decreased levels under treatment T2 (480 mOsm). Between the two 
treatments, there were 15 proteins in common with increased levels and 7 
proteins in common with decreased levels (Figure 3.2). The list of dysregulated 
proteins is shown in Table 3.3 and a heatmap of these proteins are shown in Figure 
3.6. 
 
Data from iTRAQ-based proteomics have been deposited to the ProteomeXchange 
















AKR1B1 P15121 Aldose reductase  1.47* 2.06* 
ANXA1 P04083 Annexin A1  1.27 1.85* 
ATP1A1 P05023 Sodium/potassium-transporting ATPase subunit alpha-1  1.25 1.60* 
ATP5C1 P36542 ATP synthase subunit gamma, mitochondrial  1.31 1.46* 
BZW1 Q7L1Q6 Basic leucine zipper and W2 domain-containing protein 1  1.71* 1.95* 
CANX P27824 Calnexin  1.26 1.53* 
CCT7 Q99832 T-complex protein 1 subunit eta  0.64* 0.82 
CPNE3 O75131 Copine-3  0.54* 0.45 
CPS1 P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial  1.30 1.49* 
DDOST P39656 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 
kDa subunit  
1.57* 1.56* 
DDX3X O00571 ATP-dependent RNA helicase DDX3X  1.36 1.56* 
DDX5 P17844 Probable ATP-dependent RNA helicase DDX5  0.91 1.67* 
DNAJA2 O60884 DnaJ homolog subfamily A member 2  0.67* 0.99 
DPH5 Q9H2P9 Diphthine synthase  0.48* 0.90 
DYNC1H1 Q14204 Cytoplasmic dynein 1 heavy chain 1  0.70* 0.79 
EEF1A2 Q05639 Elongation factor 1-alpha 2  0.94 0.65* 
EEF2 P13639 Elongation factor 2  1.14 1.54* 












EIF4A1 P60842 Eukaryotic initiation factor 4A-I  1.28 1.67* 
EIF4A3 P38919 Eukaryotic initiation factor 4A-III  0.99 1.66* 
EIF5 P55010 Eukaryotic translation initiation factor 5  1.05 1.65* 
EIF6 P56537 Eukaryotic translation initiation factor 6  0.64* 0.98 
EPRS P07814 Bifunctional aminoacyl-tRNA synthetase  0.70* 0.79 
ERP29 P30040 Endoplasmic reticulum resident protein 29  1.31 1.41* 
GNB1 P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  0.19* 0.72 
GRWD1 Q9BQ67 Glutamate-rich WD repeat-containing protein 1  1.79* 0.77 
HIST1H4A P62805 Histone H4  1.58* 1.75* 
HSPA5 P11021 78 kDa glucose-regulated protein (Heat shock 70 kDa protein 5) 1.13 1.58* 
HYOU1 Q9Y4L1 Hypoxia up-regulated protein 1  0.79 0.60* 
KRT10 P13645 Keratin, type I cytoskeletal 10  0.87 1.56* 
KRT7 P08729 Keratin, type II cytoskeletal 7  0.65* 0.72 
KRT8 P05787 Keratin, type II cytoskeletal 8  1.23 1.56* 
LCP1 P13796 Plastin-2  0.76 0.63* 
LDHA P00338 L-lactate dehydrogenase A chain  1.31 1.60* 
LSM7 Q9UK45 U6 snRNA-associated Sm-like protein 1.21 2.09* 
MAP2K3 P46734 Dual specificity mitogen-activated protein kinase kinase 3  0.87 1.62* 
MYO1G B0I1T2 Myosin-Ig  0.65* 0.87 
NAP1L1 P55209 Nucleosome assembly protein 1-like 1  0.90 1.58* 












NSUN2 Q08J23 tRNA (cytosine-5-)-methyltransferase 0.52* 0.98 
NUP155 O75694 Nuclear pore complex protein  0.65* 0.67* 
OGDH Q02218 2-oxoglutarate dehydrogenase, mitochondrial  1.22 1.48* 
PDHB P11177 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  1.49* 0.96 
PKM2 P14618 Pyruvate kinase isozymes M1/M2  1.13 1.53* 
PLEC Q15149 Plectin  1.42* 2.17* 
PPIB P23284 Peptidyl-prolyl cis-trans isomerase B  1.19 1.41* 
PRDX1 Q06830 Peroxiredoxin-1  1.23 1.77* 
PRDX2 P32119 Peroxiredoxin-2  0.82 0.64* 
PRPS1 P60891 Ribose-phosphate pyrophosphokinase 1  0.71 0.66* 
PSMD1 Q99460 26S proteasome non-ATPase regulatory subunit 1  0.65* 0.66* 
PSMD2 Q13200 26S proteasome non-ATPase regulatory subunit 2  0.68* 0.82 
PTGS2 P35354 Prostaglandin G/H synthase 2  1.75* 3.35* 
PTMA P06454 Prothymosin alpha  0.68 1.56* 
PXN P49023 Paxillin  0.91 0.70* 
PYGB P11216 Glycogen phosphorylase, brain form  1.45 1.46* 
RHOC P08134 Rho-related GTP-binding protein RhoC  1.52* 1.45 
RPL21 P46778 60S ribosomal protein L21  0.98 1.61* 
RPN2 P04844 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2  
1.64* 1.75* 












SERBP1 Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein  1.45* 1.43 
SERPINB3 P29508 Serpin B3  1.02 0.60* 
SLPI P03973 Antileukoproteinase  1.16 1.74* 
STOM P27105 Erythrocyte band 7 integral membrane protein  1.50* 1.14 
TGM2 P21980 Protein-glutamine gamma-glutamyltransferase 2  0.68* 0.57* 
TIMP1 P01033 Metalloproteinase inhibitor 1  0.88 1.53* 
TOMM34 Q15785 Mitochondrial import receptor subunit T 0.44* 0.79 
TOMM6 Q96B49 Mitochondrial import receptor subunit T 1.43* 1.03 
TPBG Q13641 Trophoblast glycoprotein  1.34 1.48* 
TUBB2C P68371 Tubulin beta-2C chain  1.17 1.65* 
UAP1 Q16222 UDP-N-acetylhexosamine pyrophosphorylase  1.79* 2.87* 
UBXN1 Q04323 UBX domain-containing protein 1  1.00 0.70* 
VDAC1 P21796 Voltage-dependent anion-selective channel protein 1  1.49* 1.48* 
VIM P08670 Vimentin  1.32 1.54* 
WARS P23381 Tryptophanyl-tRNA synthetase, cytoplasmic  0.90 0.59* 
XRCC5 P13010 X-ray repair cross-complementing protein 5  0.77 0.71* 
XRN2 Q9H0D6 5'-3' exoribonuclease 2  1.55 0.59* 
























































































3.3.4. Osmotic Stress Response 
The heat shock protein (HSP) response is a well-studied adaptation to cellular 
stress (127). While fourteen HSPs were detected in IOBA-NHC lysates, only HSPA5 
showed increased levels under treatment T2. As the cultures were treated for 24 h, 
it was not possible to detect rapid and transient changes in HSP levels in response 
to hyperosmotic stress, as Li et al. had demonstrated with HEK293 cultures (128). 
Li et al. had also found HSPA5 levels to be persistently elevated when HEK293 cells 
were cultured in hyperosmotic media for up to two passages (128). These results 
suggest that HSPA5 up-regulation could be a response to chronic hyperosmotic 
stress in ocular surface tissue. This study also identified increased levels of 
intermediate filament proteins, such as keratin 8 and vimentin, that are suggested 
to play cytoprotective roles similar to the classic heat shock response  (129). 
 
3.3.5. Hexosamine Pathway 
In this study, a significant increase in UDP-N-acetylglucosamine was observed 
under T2 (Table 3.1, Figure 3.7). UAP1, the enzyme responsible for UDP-N-
acetylglucosamine synthesis, was increased under T1 and T2 (Table 3.1, Figure 3.7). 
UDP-N-acetylglucosamine is a key intermediate between the hexosamine and cell 
signalling pathway as it provides the substrate for O-linked β-N-acetylglucosamine 
glycosylation (O-GlcNAcylation) of serine and threonine residues. This post-
translational modification is critical in modulating protein function, degradation 
and localisation; and is suggested to be a rapid survival response to cellular stress. 
(130)., demonstrating concordance between findings gleaned from both 
metabonomic and proteomic analysis. The increase in UAP1 levels under 




Figure 3.7 A) Synthesis pathway of glycerophosphocholine, OGT: O-GlcNAc 
transferase, OGA: O-GlcNAc-ase. B) Relative amount of UAP1 in control, T1 and 
T2. C) Relative amount of UDP-N-acetylglucosamine in control, T1 and T2 cell 
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Herzog et al. recently showed that increasing the levels of O-GlcNAcylation in 
mesothelial cells improved cell viability when the cultures were treated were 
hyperosmotic peritoneal dialysis fluid (131). Targeting the levels of O-
GlcNAcylation in ocular surface tissues may be a novel therapy to potentiate cell 
survival in dry eye disease. 
 
3.3.6. Summary for Metabonomic and Proteomic Analysis of 
an In Vitro Model of Dry Eye Disease 
 
Using global metabonomic analysis, this study identified dose-dependent increases 
in glycerophosphocholine levels in IOBA-NHC cells under hyperosmotic stress. This 
trend was verified by targeted metabonomic analysis, showing that 
glycerophosphocholine is the preferred osmoprotectant over other endogenous 
metabolites such as carnitine. In addition, this study also indentified activation of 
the hexosamine pathway from increased levels of UDP-N-acetylglucosamine and 
UAP1 under hyperosmotic stress, identified using global metabonomic analysis and 
iTRAQ-based proteomic analysis respectively. 
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4. Plasma Metabotyping of Diabetic Retinopathy 
 
4.1. Introduction to Diabetic Retinopathy 
 
Diabetic retinopathy (DR) is the most common microvascular complication of 
diabetes and the leading cause of visual impairment in working-age adults 
worldwide (55, 56). The disease is characterised by retinal haemorrhage, 
aneurysms, neo-vascularisation of the retina. The early stage of DR is 
asymptomatic (132). The global prevalence of diabetes is rising and the number of 
diabetic persons is projected to increase by 54% between 2010 and 2030 (133). 
The public health burden of diabetes and its complications would thus increase 
correspondingly. In Singapore, the prevalence of diabetes is 23% in the Malay 
ethnic group and 33% in the Indian (South-Asian) ethnic group (134, 135). The 
prevalence of DR among diabetic persons in the Malay and Indian ethnic groups in 
Singapore are 35% and 30% respectively (134, 135). 
 
There is no pharmacological treatment available for the early stages of DR. The 
major risk factors of DR are poor glycaemic control, hypertension, dyslipidaemia, 
and the duration of diabetes (136, 137). The effects of risk factor-management on 
DR prevention and control vary among study populations (56, 138). The results 
from randomised controlled trials show that a significant proportion of patients 
assigned to intensive control of metabolic risk factors continue to develop diabetic 
complications (139, 140). There is increasing evidence to suggest that metabolic 
memory is responsible for this observation. The term metabolic memory refers to 
the persistent epigenetic modifications caused by early exposure to 
hyperglycaemia that in turn predispose individuals to development of diabetic 
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complications even after good glycaemic control is achieved (141). More recently, 
Zavrelova et al. found that the progression of DR in a treated cohort occurs in 
distinct patterns, ranging from a stable condition that is free from DR to rapid 
progression to the proliferative DR within six years (142). The mechanisms 
responsible for these patterns in disease progression are unclear, and the 
contribution of the duration of diabetes towards these patterns is also not known 
(143). The discovery of biomarkers that characterise the different developmental 
phenotypes of DR thus become important as these biomarkers may provide insight 
on pathogenic pathways that are currently unknown. With an increase in the 
prevalence of diabetes (133), there is an interest to stratify patients into low and 
high risk groups of DR progression, and optimise resources for DR screening.  
 
Recent metabonomic studies have uncovered plasma and sera metabolic 
signatures associated with, or predictive of impaired glucose tolerance and 
diabetes (57-66). Furthermore, DR is a complex disease where findings from 
genome-wide-association studies have not been conclusive (67). We postulate that 
a metabolic signature of DR exists, and can be resolved from that of diabetes 
alone. Barba et al. identified metabolite markers of DR in the vitreous humour 
(21). However, the invasive nature of vitreous sampling limits study replication and 
the translational potential of any biomarkers identified from vitreous fluid. On the 
other hand, plasma or sera have remained the biofluid of choice in metabonomic 
studies. With these biological matrices, several research groups have reported 




These studies however, did not account for confounders and co-morbidities such 
as medication use and kidney disease. In this chapter, we sought to investigate if 
the plasma metabotype of DR is resolvable from the metabolic perturbations 
associated with underlying diabetes, and to identify metabolite markers of DR.  
 
4.2. Methods in Profiling Plasma Samples 
 
4.2.1. Sample Selection 
Samples were selected from banked plasma collected as part of the Singapore 
Indian Eye Study (68). The study was approved by the SingHealth Institutional 
Review Board, conducted in accordance to the Declaration of Helsinki, and written 
informed consent was obtained from all participants. Forty samples were selected 
from diabetic participants with moderate non-proliferative DR (level 43 on the 
early treatment of diabetic retinopathy scale) (148) or worse in at least one eye. 
Forty control samples were selected from retinopathy-free diabetic participants 
with comparable duration of diabetes. 
 
4.2.2. GC-MS Metabonomic Profiling 
Plasma samples (100 µL aliquots in microcentrifuge tubes) were thawed to room 
temperature (25 °C). 20 µL of D-27 myristic acid in methanol (200 µg/mL) and 300 
µL of methanol were added to each sample. The tubes was mixed for 15 min at 
room temperature and centrifuged for 10 min at 16,000 g (4 °C). 300 µL of each 
supernatant was transferred carefully to a glass tube and dried under nitrogen gas. 
The dried samples were re-suspended in 100 µL of toluene, vortexed-mixed for 10 
s and dried again under nitrogen. A two-step derivatisation method was employed 
for chemical derivatisation of metabolites. Each sample was incubated with 50 µL 
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of 2% methoxyamine chloride in pyridine (Pierce Biotechnology, Thermo Scientific) 
for 1.5 h at 60 °C. Next, 50 µL of N-methyl-N-trifluoroacetamide (Thermo Scientific) 
was added and the samples were incubated again at 60 °C for 1 h. 80 µL of 
derivatised samples were transferred to silanised glass vials for GC-MS analysis. A 
maximum of thirty-six samples were prepared each day to ensure GC-MS data 
acquisition was performed within 48 h post-derivatisation. Ten aliquots of pooled 
human plasma collected with K2EDTA tubes (Innovative Research Inc, batch 
052511), three aliquots of distilled water and 10 mM glucose in distilled water 
were also subject to the same sample pre-treatment procedure as the plasma 
samples. 
 
GC-MS analysis was performed with an Agilent 6890N gas chromatograph (Agilent 
Technologies, Santa Clara, CA, USA) coupled to Leco Pegasus III (4D) GC × GC-MS 
TOF mass analyser operating in GC-MS mode (Leco Corporation, St. Joseph, MI, 
USA). Sample injection was performed by a CTC PAL autosampler (CTC Analytics 
AG, Zwingen, Switzerland). The injection temperature was 250 °C and injection 
volume was 1 µL, with a spilt ratio of 1:5. A capillary column with DB-1 stationary 
phase of 21.5 m × 0.25 mm, 0.25 µm film thickness (Agilent Technologies) was 
used with a constant helium carrier gas flow of 1.5 mL/min. The temperature 
gradient was held at 70 °C for 2 min, increased at a rate of 10 °C/min to 310 °C, and 
held at 310 °C for 6 min. The transfer line and ion source temperatures were 280 
and 250 °C respectively. Mass spectra were acquired after a delay of 240 s post-
injection, from m/z 45 to 600 at 20 Hz using ionisation energy of 70 eV and a 
detector voltage of 1650 V. Blanks and glucose standards were injected at the 
beginning, in the middle and at the end of the sample batch. The ten pooled 
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plasma aliquots were injected before the start of the first study sample and after 
every ten clinical samples to act as quality controls (QCs). 
 
4.2.3. Data Processing 
Deconvolution and peak finding were performed with ChromaTOF (version 4.44, 
Leco Corporation) using these parameters: (i) a S/N threshold of 150, (ii) a 
minimum peak width of 2.5 s and (iii) a minimum of two apexing masses. 
Instrument performance was assessed using the peak area of D-27 myristic acid. 
 
Peak alignment was performed with the “calibration” function in ChromaTOF 
(149). In this method, a reference table was first built using data obtained from 
plasma samples of participants who had declared no medication usage. There 
were three such participants (2 DR, 1 non-DR) among the selected samples. An 
additional six samples were selected from diabetic participants in the Singapore 
Indian Eye Study who had declared no medication usage for the purpose of 
building the reference table. Each peak was only included in the reference table for 
statistical analysis if (i) it was detected in at least seven out of nine medication-free 
samples (78%) and (ii) its average integrated peak area was at least five times 
greater than that of the glucose standards and blanks. This strategy was to ensure 
that the peaks in the reference table included endogenous metabolites as 
represented in the medication-free samples and excluded xenobiotics such as 
drugs and their associated metabolites. Peaks derived from glucose were saturated 
in most samples and were thus excluded from the reference table. Furthermore, 
plasma glucose levels were not significantly different between DR and non-DR 
participants in this study. 
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Data from the analysed plasma samples representing DR and non-DR phenotypes 
in the absence and presence of kidney disease were then aligned to the reference 
table. Peaks with missing values in more than 20% of the samples were discarded. 
For those with missing values in less than 20% of the samples, the missing values 
were filled with half of the lowest value obtained for that peak across all samples. 
The raw peak area was normalised to the total peak area of all peaks within the 
90th percentile of peak area distribution in each sample, using the median sample 
as the denominator in the calculation of normalisation factors. Normalised data 
was then log transformed (base 2). Peaks with CV greater than 30% in the QC 
samples were not considered for further analysis.  
 
4.2.4. Statistical Analysis 
PCA with unit variance scaling was performed to evaluate the presence of 
dominating trends in the peak data. Mann-Whitney U tests were performed to 
identify metabolite markers of DR (p less than 0.05, fold change greater than 1.2 or 
less than 0.8). FDR correcting for multiple testing was calculated with the 
Benjamini-Hochberg method (150). The areas under curve (AUC) in receiver 
operating characteristic (ROC) analysis were calculated to evaluate the 
discriminating power of the metabolite markers (151). Logistic regression models 
were calculated to evaluate the association of metabolite peak areas with the 
presence of DR. PCA was performed with SIMCA (Umetrics). Mann-Whitney U 
tests, ROC analyses and logistic regression were performed in the R environment.  
 
4.2.5. Metabolite Identification 
Only metabolite markers with a CV less than 30% in the QC samples were 
identified. Experimentally-obtained spectra were searched against entries in the 
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National Institutes of Science and Technology (NIST) library (built-in with 
ChromaTOF) for putative identifications of metabolites. Metabolite identities were 
confirmed if both the forward and reverse similarity scores were above 800 and 
the Kovats retention index was within 2% from database entries. Peaks that could 
not be identified in the NIST library were exported to text spectra and searched 
against the Golm Metabolome Database (152). Ambiguous identifications were 
resolved by injection of derivatised analytical standards. For metabolites forming 
multiple derivatisation peaks, the peaks with lower CV in QC samples were 
reported. Peaks with unresolvable identifications were reported as mixtures of 
compounds. 
 
4.2.6. Pathway Analysis 
Pathway analysis was performed with MetaboAnalyst (153). Pathways were 
considered to be significantly enriched in the dataset if their p-value was less than 
0.05, and their FDR less than 0.2. 
 
4.3. Results and Discussion: Findings from 
Metabotyping of Diabetic Retinopathy 
 
4.3.1. Sample Characteristics 
The clinicopathological characteristics of the selected participants are shown in 
Table 4.1. Sample groups were comparable for most metabolic and clinical 
characteristics, such as BMI, total cholesterol, LDL and HDL cholesterol. 
Participants with DR had greater percentage of HbA1c than their non-DR 
counterparts, mirroring typical epidemiological findings (135, 136). While 
increased systolic BP was identified as strong risk factor for DR in the main 
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Singapore Indian Eye Study, the difference in systolic BP between the DR and non-
DR groups in this study was not statistically significant (p=0.086). When 
participants were further stratified by HbA1c thresholds, clinicopathological 
variables between DR and non-DR groups remained comparable (p> 0.05, Table 8.3 
and Table 8.4 in the appendices).  
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Clinical Characteristics* DR Non-DR P-value 
N 40 40 - 
Gender 20 M 23 M 0.501† 
Age (years) 59 (53–66 ) 62 (52–69 ) 0.846‡ 
Diastolic BP (mm Hg) 74 (68–81 ) 77 (68–83 ) 0.516‡ 
Systolic BP (mm Hg) 146 (132–155 ) 133 (122–146 ) 0.086‡ 
BMI (kg/m2) 24.5 (23.0–28.1 ) 28.6 (23.4–30.3 ) 0.070‡ 
Serum creatinine (µM)‡ 84 (71–134 ) 80 (58–117 ) 0.092‡ 
Blood glucose, random 
(mM) 
10.4 (6.8–14.6 ) 8.3 (6.9–11.2 ) 0.109‡ 
Total cholesterol (mM) 4.50 (3.99–5.39 ) 4.38 (3.66–5.25 ) 0.320‡ 
LDL cholesterol (mM) 2.84 (2.17–3.49 ) 2.59 (2.08–3.27 ) 0.332‡ 
HDL cholesterol (mM) 0.98 (0.78–1.23 ) 1.00 (0.84–1.23 ) 0.486‡ 
Triglycerides (mM) 1.79 (1.39–2.59 ) 1.35 (0.94–2.19 ) 0.076‡ 
Blood HbA1c (%)‡ 8.2 (7.4–10.2 ) 7.4 (6.5–8.0 ) 0.001‡ 
Duration of diabetes (years) 12 (7–21 ) 11 (5–19 ) 0.374‡ 
Urine ACR (µg/mg 
creatinine) 
46.0 (16.8–161.6 ) 25.7 (13.2–56.4 ) 0.053‡ 
eGFR (mL/min/1.73 m2) 68.7 (44.6–95.9 ) 87.5 (50.7–100.9 ) 0.141‡ 
Microalbuminuria 21 14 0.115† 
Macroalbuminuria 5 2 0.235† 
Chronic Kidney Disease§ 16 11 0.237† 
On Diabetes Medication 34 32 0.556† 
* Values indicate median with interquartile range, where applicable 
† Pearson chi-square test  
‡ Mann-Whitney U test 
§ Defined as eGFR below 60 mL/min/1.73 m2 
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4.3.2. Data Table and Chemometric Analysis 
There were 263 peaks in the reference table constructed from medication-free 
samples and 258 were present in at least 80% of the samples. The CV of D-27 
myristic acid, the internal standard was 7.9% and 193 peaks had a CV of less than 
30% in the QC samples. The PCA model constructed from aligned peak data was 
optimised at 5 PCs, with R2 and Q2 values of 0.48 and 0.27 respectively. Most 
samples from participants with chronic kidney disease are located towards the 
positive scores along the first PC (Figure 4.1A). When labelled by HbA1c values, the 
majority of samples with greater HbA1c levels are found on the positive axis of the 
second PC (Figure 4.1B). These clustering trends show that chronic kidney disease 
and glycaemic control are significant contributors to the overall plasma 





Figure 4.1 A) PCA scores plot with samples coloured by presence (red) and 
absence (blue) of chronic kidney disease. B) PCA scores plot with samples 
coloured by HbA1c levels: under 7% (blue), 7 to 8% (green), 8 to 10% (orange) 





4.3.3. Metabolite Markers of DR 
Fourteen metabolites were significantly different between the DR and non-DR 
group, based on global comparison of all DR and non-DR samples (Table 4.2).  
Subset analysis on the participants with HbA1c levels at 10% or below yielded eight 
metabolites which significantly differed between the DR and non-DR groups (Table 
4.3). Further restriction to participants with HbA1c levels between 6 to 10% 
yielded twelve metabolites which were significantly different between DR and non-
DR groups (Table 4.4). Most identified metabolite markers were concordant among 
two or more comparisons. 1,5-Anhydroglucitol, 1,5-gluconolactone, 2-deoxyribonic 
acid, gluconic acid, lactose/cellobiose and urea were consistently identified as 
metabolite markers in all three sets of comparative analysis (Figure 4.2). Analytical 
information of all identified metabolite markers are provided in Table 4.5. 
 
The odds ratios of the metabolite markers in the basic model and adjusted values 
obtained from the inclusion of systolic BP, BMI, creatinine, glucose and HbA1c 
levels are shown in Table 4.6; and adjusted values obtained from the inclusion of 
triglycerides, diabetes duration, urine albumin-to-creatinine ratio (ACR) and 
estimated glomerular filtration rate (eGFR)  are shown in Table 4.7. Adjustment for 
HbA1c levels improved model performance for the majority of the metabolites, 
including that of 1,5-anhydroglucitol, 1,5-gluconolactone, 2-deoxyribonic acid, 
gluconic acid, lactose/cellobiose and urea. The inclusion of age, gender, diastolic 
BP, total cholesterol, HDL cholesterol and LDL cholesterol levels as co-variates gave 
similar odds ratios to the basic model and did not improve model performance 
(Table 8.5 and Table 8.6 in the appendices).  
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Table 4.2 Metabolite markers identified from global metabonomic analysis of all 
samples. 
Metabolite Fold-change* P-value FDR AUC 
1,5-Anhydroglucitol† 0.50 <0.001 0.030 0.74 (0.63–0.84) 
1,5-Gluconolactone 1.45 0.001 0.058 0.71 (0.60–0.83) 
2-Deoxyribonic acid 1.60 0.007 0.138 0.68 (0.56–0.79) 
3,4-Dihydroxybutyric acid 1.26 0.019 0.226 0.65 (0.53–0.78) 
Erythritol 1.25 0.019 0.226 0.63 (0.51–0.76) 
Gluconic acid 1.57 0.001 0.037 0.72 (0.61–0.84) 
Glutamine† 0.78 0.035 0.295 0.64 (0.52–0.76) 
Hippuric acid 1.70 0.033 0.294 0.64 (0.52–0.76) 
Lactose/Cellobiose 1.75 0.010 0.142 0.67 (0.55–0.79) 
Maltose/Trehalose 1.74 0.003 0.088 0.70 (0.58–0.81) 
Mannose 1.21 0.009 0.142 0.67 (0.55–0.79) 
Myo-inositol 1.25 0.042 0.314 0.63 (0.51–0.76) 
Ribose 1.42 0.016 0.217 0.66 (0.54–0.78) 
Urea 1.35 0.004 0.093 0.69 (0.57–0.80) 
* Values above 1 indicate increase in DR samples 
† Classification in ROC was reversed for metabolites with fold-change less than 1 
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Table 4.3 Metabolite markers identified from subset of participants with HbA1c 
levels at 10% or below.  
Metabolite Fold-change* P-value FDR AUC 
1,5-Anhydroglucitol† 0.55 0.001 0.115 0.73 (0.61–0.85) 
1,5-Gluconolactone 1.39 0.010 0.287 0.68 (0.55–0.81) 
2-Deoxyribonic acid 1.55 0.029 0.459 0.65 (0.52–0.79) 
alpha-Ketoisovalerate† 0.80 0.001 0.115 0.74 (0.63–0.86) 
Gluconic acid 1.71 0.043 0.287 0.68 (0.55–0.81) 
Hippuric acid 1.42 0.012 0.543 0.64 (0.51–0.77) 
Lactose/Cellobiose 1.67 0.029 0.459 0.65 (0.52–0.79) 
Urea 1.39 0.003 0.164 0.71 (0.58–0.83) 
* Values above 1 indicate increase in DR samples 
† Classification in ROC was reversed for metabolites with fold-change less than 1 
 
 
Table 4.4 Metabolite markers identified from subset of participants with HbA1c 
levels between 6 to 10%. 
Metabolite Fold-change* P-value FDR AUC 
1,5-Anhydroglucitol† 0.55 0.002 0.110 0.73 (0.61–0.85) 
1,5-Gluconolactone 1.41 0.010 0.231 0.69 (0.61–0.84) 
2-Deoxyribonic acid 1.66 0.013 0.240 0.68 (0.55–0.81) 
3-Methyl-2-oxovaleric acid 0.79 0.005 0.177 0.71 (0.58–0.82) 
alpha-Ketoisovalerate† 0.78 <0.001 0.082 0.76 (0.65–0.88) 
Erythritol 1.27 0.031 0.359 0.65 (0.51–0.86) 
Erythronic acid 1.23 0.049 0.446 0.66 (0.52–0.35) 
Gluconic acid 1.42 0.016 0.270 0.68 (0.54–0.85) 
Inositol phosphate  1.21 0.039 0.396 0.65 (0.51–0.79) 
Lactose/Cellobiose 1.79 0.014 0.252 0.68 (0.54–0.81) 
Myo-inositol 1.30 0.025 0.309 0.66 (0.52–0.81) 
Urea 1.45 0.002 0.110 0.73 (0.61–0.82) 
* Values above 1 indicate increase in DR samples 





Figure 4.2 Concordance of DR metabolite markers identified from (i) all samples, 
(ii) subset of samples with HbA1c levels at 10% or below and (iii) subset of 
samples with HbA1c levels between 6 to 10%. Arrows indicate the direction of 
change in DR samples, compared with non-DR samples. 
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CV in QC 
samples 
1,5-Anhydroglucitol 1882 217 5 
1,5-Gluconolactone* 1910 319 15 
2-Deoxyribonic acid 1689 233 13 
3,4-Dihydroxybutyric acid 1447 233 8 
3-Methyl-2-oxovaleric acid 1193 200 13 
α-Ketoisovalerate 1129 202 15 
Erythritol* 1546 217 5 
Erythronic acid 1575 292 7 
Gluconic acid* 2064 333 13 
Glutamine 1629 246 14 
Hippuric acid* 1796 105 10 
Inositol phosphate 2486 318 22 
Lactose/Cellobiose† 2800 361 11 
Maltose/Trehalose† 2845 361 4 
Mannose* 1941 319 7 
Myo-inositol* 2156 305 4 
Ribose* 1718 217 11 
Urea 1236 189 5 
* Verified with analytical standard 







Table 4.6 Odds ratio of metabolite markers adjusted for systolic BP, BMI, creatinine, glucose and HbA1c. 
Metabolite 
Odds ratio, per s.d. increment in metabolite peak area (95% CI) 
Basic Model + Systolic BP + BMI + Creatinine + Glucose + HbA1c 
1,5-Anhydroglucitol 0.37 (0.19–0.65)* 0.36 (0.19–0.64)* 0.35 (0.18–0.62)* 0.38 (0.19–0.67)* 0.40 (0.21–0.71)* 0.51 (0.25–0.97)*‡ 
1,5-Gluconolactone 2.40 (1.38–4.65)* 2.58 (1.46–5.05)* 2.52 (1.44–4.91)* 2.63 (1.36–5.69)* 2.21 (1.25–4.35)* 2.28 (1.24–4.78)*‡ 
2-Deoxyribonic acid 2.08 (1.25–3.76)* 2.22 (1.32–4.11)* 2.19 (1.31–4.03)* 2.92 (1.31–7.58)* 1.97 (1.16–3.61)*§ 2.14 (1.22–4.14)*‡ 
3,4-Dihydroxybutyric acid 1.61 (1.01–2.70)† 1.67 (1.05–2.80)* 1.63 (1.02–2.73)* 1.49 (0.88–2.61) 1.56 (0.96–2.62)†‡ 1.51 (0.91–2.59)‡ 
3-Methyl-2-oxovaleric acid 0.81 (0.50–1.27) 0.78 (0.48–1.23) 0.75 (0.46–1.18) 0.94 (0.55–1.58) 0.68 (0.40–1.12)‡ 0.44 (0.22–0.82)*‡ 
α-Ketoisovalerate 0.58 (0.34–0.93)* 0.55 (0.32–0.89)* 0.54 (0.31–0.88)* 0.61 (0.33–1.07)† 0.54 (0.30–0.89)*‡ 0.31 (0.14–0.59)*‡ 
Erythritol 1.68 (1.04–2.85)* 1.75 (1.08–2.97)* 1.79 (1.10–3.07)* 1.79 (0.86–3.99) 1.64 (1.00–2.82)†‡ 1.71 (1.02–3.05)†‡ 
Erythronic acid 1.57 (0.97–2.71)† 1.67 (1.02–2.93)† 1.59 (0.98–2.75)† 1.53 (0.71–3.46) 1.62 (0.98–2.92)†‡ 1.97 (1.11–3.88)*‡ 
Gluconic acid 2.65 (1.50–5.33)* 2.76 (1.55–5.57)* 2.75 (1.54–5.54)* 2.83 (1.47–6.25)* 2.49 (1.30–5.38)* 2.04 (1.10–4.20)*‡ 
Glutamine 0.51 (0.28–0.86)* 0.52 (0.29–0.86)* 0.56 (0.31–0.92)* 0.53 (0.29–0.87)* 0.48 (0.25–0.81)*‡ 0.53 (0.28–0.90)*‡ 
Hippuric acid 1.71 (1.05–2.98)* 1.75 (1.07–3.06)* 1.66 (1.00–2.93)† 1.61 (0.91–2.98) 1.78 (1.06–3.20)*‡ 2.05 (1.16–3.97)*‡ 
Inositol phosphate 1.26 (0.80–2.03) 1.34 (0.85–2.15) 1.46 (0.92–2.40)§ 1.30 (0.82–2.12) 1.52 (0.93–2.58)‡ 1.69 (1.01–2.99)†‡ 
Lactose/Cellobiose 1.78 (1.10–3.01)* 1.93 (1.19–3.29)* 1.79 (1.11–3.05)* 1.68 (0.98–3.02)† 1.72 (1.05–2.96)*§ 1.92 (1.13–3.51)*‡ 
Maltose/Trehalose 2.14 (1.29–3.84)* 2.01 (1.21–3.57)* 2.04 (1.24–3.59)* 2.09 (1.26–3.75)* 1.94 (1.07–3.74)* 1.46 (0.80–2.82)‡ 
Mannose 1.81 (1.09–3.27)* 1.65 (1.00–2.93)† 1.73 (1.06–3.04)* 1.88 (1.13–3.40)*§ 1.62 (0.97–2.79)†§ 1.34 (0.74–2.35)‡ 
Myo-inositol 1.60 (0.99–2.76)† 1.69 (1.04–2.95)* 1.83 (1.11–3.24)*§ 1.64 (0.74–3.82) 1.56 (0.95–2.72)†‡ 1.65 (0.97–3.05)†‡ 
Ribose 1.65 (1.02–2.80)* 1.68 (1.04–2.85)* 1.62 (1.01–2.76)† 1.52 (0.90–2.71) 1.57 (0.96–2.72)†§ 1.49 (0.89–2.64)‡ 
Urea 1.95 (1.18–3.48)* 2.17 (1.30–3.95)*§ 2.08 (1.25–3.74)* 2.12 (1.09–4.36)* 2.07 (1.20–3.91)*‡ 2.50 (1.39–4.98)*‡ 







Table 4.7 Odds ratio of metabolite markers adjusted for triglycerides, diabetes duration, urine ACR and eGFR. 
Metabolite 
Odds ratio, per s.d. increment in metabolite peak area (95% CI) 
Basic Model + Triglycerides + Diabetes Duration + Urine ACR + eGFR 
1,5-Anhydroglucitol 0.37 (0.19–0.65)* 0.34 (0.16–0.61)* 0.37 (0.19–0.64)* 0.39 (0.20–0.70)* 0.37 (0.19–0.65)* 
1,5-Gluconolactone 2.40 (1.38–4.65)* 2.49 (1.42–4.83)* 2.38 (1.36–4.65)* 2.24 (1.25–4.41)* 2.82 (1.43–6.31)* 
2-Deoxyribonic acid 2.08 (1.25–3.76)* 2.14 (1.27–3.89)* 2.10 (1.24–3.86)* 1.91 (1.11–3.55)* 3.43 (1.49–9.20)* 
3,4-Dihydroxybutyric acid 1.61 (1.01–2.70)† 1.63 (1.02–2.71)* 1.59 (0.99–2.67)† 1.49 (0.92–2.51) 1.55 (0.90–2.82) 
3-Methyl-2-oxovaleric acid 0.81 (0.50–1.27) 0.75 (0.46–1.17) 0.82 (0.51–1.30) 0.89 (0.54–1.45)§ 0.91 (0.53–1.55) 
α-Ketoisovalerate 0.58 (0.34–0.93)* 0.55 (0.32–0.89)* 0.58 (0.34–0.94)* 0.63 (0.36–1.03)† 0.58 (0.31–1.03)† 
Erythritol 1.68 (1.04–2.85)* 1.73 (1.07–2.93)* 1.67 (1.02–2.87)* 1.50 (0.89–2.62) 2.15 (0.97–5.33)† 
Erythronic acid 1.57 (0.97–2.71)† 1.62 (1.01–2.80)† 1.56 (0.95–2.74)† 1.39 (0.82–2.48) 1.68 (0.80–3.88) 
Gluconic acid 2.65 (1.50–5.33)* 2.75 (1.53–5.56)* 2.64 (1.49–5.31)* 2.47 (1.37–5.03)* 2.87 (1.50–6.30)* 
Glutamine 0.51 (0.28–0.86)* 0.52 (0.29–0.86)* 0.51 (0.28–0.85)* 0.52 (0.28–0.88)*§ 0.53 (0.29–0.88)* 
Hippuric acid 1.71 (1.05–2.98)* 1.75 (1.08–3.03)* 1.69 (1.03–2.98)† 1.70 (0.98–3.09)† 1.66 (0.95–3.03)† 
Inositol phosphate 1.26 (0.80–2.03) 1.41 (0.90–2.29) 1.25 (0.79–2.02) 1.27 (0.80–2.06)§ 1.28 (0.81–2.07) 
Lactose/Cellobiose 1.78 (1.10–3.01)* 1.84 (1.15–3.11)* 1.77 (1.09–3.02)* 1.64 (1.00–2.81)† 1.77 (1.02–3.25)† 
Maltose/Trehalose 2.14 (1.29–3.84)* 2.03 (1.23–3.60)* 2.17 (1.30–3.91)* 2.05 (1.23–3.67)* 2.15 (1.29–3.87)* 
Mannose 1.81 (1.09–3.27)* 1.64 (1.01–2.89)† 1.86 (1.11–3.38)* 1.81 (1.08–3.31)*§ 2.00 (1.19–3.70)*§ 
Myo-inositol 1.60 (0.99–2.76)† 1.68 (1.03–2.91)* 1.58 (0.98–2.74)† 1.41 (0.82–2.53) 1.86 (0.84–4.58) 
Ribose 1.65 (1.02–2.80)* 1.70 (1.06–2.91)* 1.63 (1.01–2.78)† 1.57 (0.96–2.70)† 1.57 (0.94–2.76)† 
Urea 1.95 (1.18–3.48)* 2.07 (1.25–3.72)* 1.94 (1.17–3.47)* 1.83 (1.10–3.26)* 2.78 (1.28–6.69)* 






4.3.4. Metabolite Markers Complementary to Known Risk 
Factors 
To improve existing risk stratification of DR-free diabetic patients and those 
suffering from early stages of DR, it is relevant to identify metabolite markers  of 
DR that are complementary to known risk factors such as poor glycaemic control 
and hypertension (136, 137). From Figure 4.2, we observe that hippuric acid 
remains a metabolite marker among the subset of participants with HbA1c levels 
at 10% and below. Erythritol and myo-inositol are also metabolite markers among 
the subset of participants with HbA1c levels between 6 to 10%. More importantly, 
we have identified a robust panel of metabolite markers which are not only 
independent of HbA1c, but also remain statistically significant when adjusted for 
known metabolic risk factors for DR and potentially confounding kidney disease. 
From Table 4.6 and Table 4.7, we observe that 1,5-gluconolactone, 2-deoxyribonic 
acid, gluconic acid and urea retain significant odds ratios when adjusted for systolic 
BP, BMI, triglycerides, blood glucose, HbA1c, duration of diabetes, urine ACR and 
eGFR. 
 
4.3.5. Pathways Associated with DR 
Pathway mapping on MetaboAnalyst (153) demonstrated that the pentose 
phosphate and galactose metabolism pathways are significantly enriched among 
the metabolite markers in these results. The pentose phosphate pathway was 
identified with 1,5-gluconolactone, gluconic acid and ribose; while galactose 
metabolism was identified with lactose, mannose and myo-inositol (Table 4.8). 
These results suggest the implications of selected metabolite classes (organic acids, 
polyols and sugars, oxidative stress markers and co-metabolites of microbial 
metabolism) in DR pathogenesis and further studies are warranted. 
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Table 4.8 Metabolic pathways dysregulated in DR. 
 
 
3,4-Dihydroxybutyric acid was identified as a metabolite marker in the global 
comparison of all selected participants (Table 4.2) while 2-deoxyribonic was 
identified as a metabolite marker in both the global comparison and subset 
analyses (Table 4.2, Table 4.3, Table 4.4, Figure 4.2). These two metabolites have 
not been reported to be associated with diabetes or DR, nor are they curated in 
the major metabolic major databases such as KEGG (100), Reactome (154) and 
MetaCore. 3,4-Dihydroxybutyric acid is a urinary marker for succinate 
semialdehyde dehydrogenase deficiency (155) while the presence of 2-
deoxyribonic acid within DNA is an indication of oxidative damage  to the sugar 
moiety (156). Further investigations of the function of 2-deoxyribonic acid and 
correlation studies between free metabolite 2-deoxyribonic acid and DNA-bound 
2-deoxyribonic acid are required to establish its relevance in DR pathogenesis. 
 
Increased polyol pathway flux is one of the main driving hypotheses responsible 
for diabetic vascular complications (157). Increased aldose reductase activity under 
hyperglycemic conditions consumes NADPH. This affects regeneration of reduced 
glutathione, thereby induces or worsens underlying oxidative stress. While Barba 
et al. established indirect evidence of increased polyol pathway flux in the analysis 
of vitreous humour of DR patients (21), increases in plasma levels of sorbitol and 


















with DR in our study. This is likely attributable to localisation of aldose reductase 
activity on glucose in susceptible cell types—in this case, retina capillary 
endothelium (157). As a result, this perturbation remains undetected in systemic 
circulation such as plasma. The pentose phosphate pathway is the main source of 
cellular NADPH. Liu et al. had identified activation of the pentose phosphate 
pathway in adiponectin knock-out mice on a high-fat diet (158). This was 
associated with disturbances in glucose homeostasis and lipid metabolism. The 
activation pentose phosphate pathway in our study (Table 4.8), particularly the 
increases in metabolites in the oxidative stage of the pentose pathway allude to 
involvement of oxidative stress in the pathogenesis of DR (Figure 4.3). 
 
Erythritol is recommended as a diabetic-safe sweetener as it is a metabolically 
inert anti-oxidant (159). Earlier metabonomic studies have identified erythritol as a 
marker of diabetes (64) and impaired fasting glucose (59). In this study, plasma 
erythritol levels were increased in DR participants in the global comparison and 
among the subset of participants with HbA1c between 6 to 10% (Table 4.2, Table 
4.4, Figure 4.2). In the absence of dietary survey data, it is unclear if the observed 
trends in erythritol levels were due to increased consumption of sweeteners or DR-
related metabolic dysregulation. Mannose, a metabolite in galactose metabolism 
was previously identified as a marker for impaired fasting glucose (58, 59) and 
diabetes (58, 64). In this study, plasma mannose levels were increased in DR 
participants in the global comparison (Table 4.2, Figure 4.2). Therefore future 
studies targeting the quantitation of polyols and sugars are pertinent as 
metabolites in the pentose phosphate and galactose pathways are potential 
clinical metabolite markers of DR. Dietary information should also be incorporated 
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to allow the distinct identification of metabolite markers associated with DR from 
metabolic perturbations that directly result from nutritional factors. 
 
There is accumulating evidence to support the contribution of altered gut 
microbiota to obesity and diabetes (160). More recently, metagenome-wide 
association studies demonstrated the association of gut microbial dysbiosis with 
type 2 diabetes (161, 162). Hippuric acid is a co-metabolite of gut microbiota 
derived from benzoic acid (163). The identification of hippuric acid as a metabolite 
marker (Table 4.2, Table 4.3) suggests that altered gut microbiota could contribute 
to DR pathogenesis. Further studies would be required to determine the roles of 
gut microbiota composition and microbial co-metabolism in DR and other vascular 








Figure 4.3 Activation of the pentose phosphate pathway identified from elevated 1,5-gluconolactone, gluconic acid and ribose (red arrows) levels in DR 
patients. Reactions marked with an asterisk produce NADPH. Green arrows denote the accumulation of glycolytic metabolites leading activation of the 
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4.3.6. Non-Replicable Findings 
There are however, several metabolite trends which have been associated with 
type 2 diabetes or DR that were not replicated in this study.  
 
Increases in plasma/sera branched chain (62-64) and aromatic (60-63) amino acids 
levels were reported as markers and predictors of type 2 diabetes, while glycine 
levels were found to be negatively correlated with diabetes (63, 65). Unlike earlier 
findings, the levels of branched chain amino acids and glycine were not 
significantly different between DR and non-DR groups in this study (Table 4.9). This 
contrast is likely due to the definition and choice of the control group. In the cited 
studies, the control samples were derived from healthy persons, while this study’s 
controls were sampled from diabetic persons who could have pre-existing 
increased catabolism of branched chain and aromatic amino acids. In addition, the 
majority of participants in this study had been prescribed with diabetes-controlling 
medication (Table 4.1). These medications might have helped to lower the 
magnitude of perturbations in amino acid metabolism compared with untreated 
diabetes.  
 
3-Hydroxybutyric acid, a ketone body,  is a marker for impaired glucose tolerance 
(57) and type 2 diabetes (64, 65). Although Li et al. reported 3-hydroxybutyric acid 
as marker of DR (22), this study did not detect an increase in plasma levels of this 
ketone body in DR participants (Table 4.9). 2-Hydroxybutyric acid, a derivative of α-
ketobutyrate, was previously reported as a marker (58, 65) and predictor (164) for 
diabetes, but its levels were not significantly different between DR and non-DR 
groups in this study (Table 4.9). These non-replicable trends imply that the plasma 
metabotype of DR is not a mere extension or subset of the metabotype of 
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diabetes. Li et al. also reported lower of plasma linoleic and arachidonic acids in DR 
participants. While this is in line with the view that arachidonic acid generally 
produces pro-inflammatory eicosanoids (165), we did not find significant 
differences in the levels of linoleic acid and arachidonic acid between DR and non-
DR participants in this study (Table 4.9). The differences between this study’s 
findings and those reported in previous literature could be due to unaccounted 
confounders. For example, Li et al. did not consider BP and diabetes duration. The 
increase in plasma aspartic acid levels identified by Li et al. (22) might potentially 
be a marker of co-morbid diabetic nephropathy (166). 
 
Omega-3 polyunsaturated fatty acids (PUFAs) are thought to aid in diabetes 
prevention but meta-analyses on omega-3 fatty acids intake show heterogeneous 
results, stratified by study locale (167). The omega-3 PUFAs, docosahexaenoic and 
eicosapentaenoic acid were detected in this study but there were no significant 
differences in the plasma levels of these PUFAs between DR and non-DR groups 
(Table 4.9). Similarly, Mäkinen et al. found that the baseline serum 
docosahexaenoic could not predict progressive kidney disease among patients 
with type 1 diabetes (168). Although omega-3 PUFAs have been shown to protect 
against DR in rodent models (169-171), their efficacy in preventing vascular 





Table 4.9 Diabetes or DR-associated metabolites in literature presenting no significant changes between DR and non-DR participants in this study. 
Compound Class Metabolite Fold-Change P-value 
Retention 
Index 
CV in QC 
samples 
Amino Acid 
Aspartic acid 0.82 0.13 1530 15 
Glycine 0.99 0.94 1317 9 
Isoleucine 0.96 0.67 1170 14 
Leucine 0.94 0.74 1150 13 
Phenylalanine 0.94 0.26 1624 11 
Tryptophan 0.97 0.33 2178 9 
Tyrosine 0.85 0.14 1871 26 
Valine 0.92 0.19 1083 11 
Hydroxy Acid 
2-Hydroxybutyric acid 0.98 0.80 1136 8 
3-Hydroxybutyric acid 1.27 0.39 1166 8 
PUFA 
Arachidonic acid 1.05 0.38 2353 18 
Docosahexaenoic acid 0.98 0.77 2538 22 
Eicosapentaenoic acid 0.92 0.20 2376 24 
Linoleic acid 0.98 0.73 2200 11 




4.3.7. Confounding Factors in Pathway Analysis. 
GC-MS is widely used in metabonomic analysis as EI ionisation is highly robust and 
reproducible, enabling the use of spectral libraries for metabolite identification. 
However, this platform is prone to confounding factors introduced through the 
sample derivatisation process or thermal degradation of metabolites at elevated 
temperatures. For example, arginine is detected as carbodiimide (172) (Kovat’s 
retention index of 972 in this study) and cyclic lactones are known to partially 
decompose to their respective sugar acids when analysed by GC-MS (173). We are 
however, confident of the identification of 1,5-gluconolactone as a marker of DR as 
it demonstrated good reproducibility in QC samples (15% CV, Table 4.5) and 
yielded a linear peak area response with concentration in standards (Pearson’s r = 
0.99, 1 to 25 μg/mL). Fatty acids detected by GC-MS reflect the total sum present 
in triglycerides, diacyglycerols and other lipids (6), and are not an accurate 
reflection of circulating free fatty acid concentrations. Future investigations on 
lipid metabolism in DR would be better investigated using a targeted lipidomics 
approach.  
 
4.3.8. Study Limitations 
This study focused on the Indian (South Asian) ethnic group as the prevalence of 
diabetes and age-adjusted DR in Indians is the highest among the major ethnic 
groups of Singapore (174). As this study design only captures a snapshot of plasma 
metabotypes, some of the identified markers are potentially a representation of 
short-term metabolic perturbations instead of chronic risk factors associated with 
development of DR. For example, 1,5-anhydroglucitol, a marker for short-term 
glycaemic control (lowered values indicate hyperglycaemia and vice-versa) was 
found to be lowered in DR participants in all comparative analysis. 
 87 
4.4. Summary for Metabotyping of Diabetic 
Retinopathy 
 
Using global metabonomic profiling, this study identified plasma metabolite 
signatures of DR which are resolvable from pre-existing diabetes and remain 
robust in the presence of confounders. The metabolite markers 1,5-
gluconolactone, urea, gluconic acid and 2-deoxyribonic acid were significantly 
different between DR and non-DR groups, even after adjustments for 
clinicopathological variables. The pentose phosphate pathway was identified as a 
key metabolic dysregulation associated with DR and points to the involvement of 
oxidative stress towards disease pathogenesis. The identification of hippuric acid, a 
microbial co-metabolite suggests that the dysregulation of the microbiome could 
be another risk factor for DR.   
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5. Investigation of SWATHTM MS for Metabonomic 
Analysis 
 
5.1. Introduction to SWATHTM Technique 
 
SWATHTM MS is a new data acquisition mode recently introduced on Q-TOF 
instruments (69). Unlike in IDA where only a limited number of precursor m/z of 
high signal intensities are selected for fragmentation, SWATHTM MS acquires 
continuous MS/MS  data in each duty cycle. This is achieved by modifying the radio 
frequency and direct current on the quadrupole to select isolation windows that 
are 10 to 25 Da wide. These selection windows are applied in steps across the 
entire precursor mass range within one duty cycle. Thus SWATHTM acquisition 
captures MS/MS information from precursors of low signal intensity that would 
have been missed by IDA. Quantitative information in SWATHTM-acquired data are 
obtained via high resolution XICs of MS/MS product ions recorded in the respective 
isolation windows where the parent m/z of the compounds of interest lie. Unlike 
conventional multiple-reaction-monitoring (MRM) quantitation methods, 
SWATHTM MS captures quantitative data of all detectable species in a sample in a 
permanent archive. These data files could be mined to validate the findings of 
discovery -omic studies without the need to develop MRM parameters for each 
compound, or to identify new candidates in the same metabolic pathways as 
newly-discovered biomarkers. 
 
Due to the width of the isolation window, quantitation by SWATHTM MS is 
susceptible to crosstalk from co-eluting precursor ions that produce fragments 
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with a similar m/z (even at high resolution). In proteomics, this issue can be 
circumvented by (i) the application of FDR filters on MS/MS spectra, (ii) the 
selection of unique ion signatures to proteins-of-interest (175), and (iii) the 
selection of other multiply-charged m/z species of the same sequence for 
quantitation.  
 
To the best of our knowledge, there is no literature available evaluating the use of 
SWATHTM MS for the analysis of underivatised endogenous metabolites. This 
chapter investigated the performance of SWATHTM MS in metabolite quantitation 
alongside conventional MRM. The metabolites evaluated are betaine, carnitine, 
glycerophoshocholine, phosphocholine, taurine, sarcosine and UDP-N-
acetylglucosamine. These metabolites were either reported to be osmoprotectants 
from literature (120, 121, 176) and/or found to be dysregulated in this study on 
IOBA-NHC cells under hyperosmotic stress earlier in this thesis. 
 
5.2. MRM and SWATHTM Quantitation Methods 
 
Metabolite standards were purchased from Sigma Aldrich. Standard solutions were 
prepared in the range of 1 to 200 ppb (pg/µL) in 4:1 ACN/water. Two MRM 
transitions were optimised for betaine, carnitine, glycerophoshocholine, 
phosphocholine, taurine and sarcosine via direct infusion. The transitions were 
optimised for DP, CE and collision exit potential (CXP). Metabolite standards were 
then analysed by MRM and SWATHTM MS.  
 
Triplicate injections were performed for each concentration. Separation in both 
quantitation methods was performed on an Agilent 1290 Infinity chromatography 
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system (Agilent Technologies) using an Atlantis HILIC silica 2.1 × 100 mm 3 µm 
column (Waters Corporation). The mobile phase was 5 mM ammonium formate 
(eluent A) and 5 mM ammonium formate (eluent B). The linear gradient profile 
was 100% B from 0 to 1 min, 20% B from 12 to 14 min, and 100% B from 15 to 19 
min. The flow rate was 0.4 mL/min and the injection volume was 10 µL for all 
standards. 
 
MRM acquisition was performed on a QTrap 6500 ion trap mass spectrometer in 
the positive ionisation polarity using optimised DP, CE and CXP parameters 
developed for each compound. The dwell time of each transition was 25 ms. For 
each metabolite, the transition with the greater intensity was used to plot a 
calibration curve in MultiQuant (AB Sciex). 
 
SWATHTM acquisition was performed with a TripleTOF 5600 Q-TOF mass 
spectrometer. Betaine, carnitine, glycerophoshocholine, phosphocholine, taurine 
and sarcosine standards were analysed in the positive ionisation polarity, while 
UDP-N-acetylglucosamine standards were analysed in the negative ionisation 
polarity. The Q1 mass range was scanned from m/z 50 to 800 in steps of 25 Da. 
MS/MS data in each step was acquired from m/z 25 to 800. The accumulation time 
for each step was 50 ms and the total duty cycle time was 700 ms. The source 
voltage was 5 kV and declustering potential was 80 V. CE was ramped from 20 to 
40 V. MS/MS spectra of the metabolite standards were also acquired to determine 
the accurate mass of their product ions. The accurate mass of the product ions 
corresponding to the MRM transition of greater intensity were extracted from 
their respective isolation windows with MultiQuant (AB Sciex).  
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5.3. Results and Discussion: Comparison of SWATHTM 
with MRM 
 
5.3.1. LOQ and Linearity of SWATHTM Quantitation 
The optimised MRM parameters of the metabolite panel are shown in Table 5.1. 
The isolation windows and MS/MS extraction masses of these metabolites are 
shown in Table 5.2. Pearson’s r values of the calibration curve and the lower limit 
of quantitation (LOQ) obtained from MRM and SWATHTM quantitation of the 
metabolite panel are shown in Table 5.3. The LOQ in this study was defined as the 
lowest concentration at which the metabolite was detectable with a CV of 20% or 
less among triplicates, and with an error of 20% or less between actual and 
calculated concentrations. The LOQ was expressed as nanograms of metabolites 
injected on column. Compared with MRM, SWATHTM quantitation yielded poorer 
(higher) LOQ for all metabolites. The r values of the calibration curve for taurine 






Table 5.1 Optimised MRM parameters of the metabolite panel. 
Compound RT (min) Q1 (m/z) Q3 (m/z) DP (V) CE (V) CXP (V) 
Betaine 5.06 118.1 58.0 90 40 10 
Carnitine 6.48 162.1 103.0 80 23 12 
Glycerophoshocholine 6.60 258.1 104.2 70 21 5 
Sarcosine 4.96 90.0 44.2 35 18 7 













Betaine 99.0–125.0 58.068 
Carnitine 149.0–175.0 103.039 
Glycerophoshocholine 249.0–275.0 104.107 
Sarcosine 74.0–100.0 44.053 
Taurine 124.0–150.0 108.010 
 
 
Table 5.3 Comparison of LOQ and Pearson’s r obtained from MRM and SWATHTM 
quantitation of the metabolite panel. 
Metabolite 
LOQ (ng) Pearson’s r 
MRM SWATHTM MRM SWATHTM 
Betaine 0.01 0.20 0.83 0.84 
Carnitine 0.01 0.10 1.00 0.97 
Glycerophoshocholine 0.01 0.10 0.98 0.92 
Sarcosine 0.05 0.20 0.99 0.96 




5.3.2. Correlation of Extracted Ions  
The top five fragments with the greatest intensity for UDP-N-acetylglucosamine 
are m/z 272.961, 282.037, 362.014, 384.983 and 403.001. Their peak areas over 
the concentration range of 10 to 100 ppb are shown in Figure 5.1. The peak area of 
m/z 403.001 in the investigated concentration range does not correlate with that 
of other fragments. This shows that SWATHTM quantitation is susceptible to 
interference in the background due the large m/z window applied in ion selection 
by the quadrupole. Compared with SWATHTM proteomics, the issue is aggravated 
in the analysis of low molecular weight metabolites. To perform accurate 
quantitation using SWATHTM MS in metabonomic analysis, two or more accurate 
mass fragments of a compound should be selected and their peak areas checked 
for linear correlation in standard injections. Interference could be reduced by 
decreasing the width of the isolation window, but at the expense of duty cycle 






Figure 5.1 Peak areas of UDP-N-acetylglucosamine fragments in standard 




















5.4. Feasibility of SWATHTM MS in Metabonomic 
Analysis 
 
Although the SWATHTM workflow has been applied in global proteomic analysis 
with free-access or in-house acquired libraries (73, 177), there are limitations to 
implementing SWATHTM acquisition in global metabonomic analysis. Firstly, there 
is no commercially-available software that is capable of (i) automated extraction of 
a large number of isolation window-fragment ion pairs from raw data or (ii) 
construction of sample-specific isolation window-fragment ion libraries from IDA 
acquisitions. Given the current limitation in informatics, SWATHTM MS is best 
limited for quantitation of known metabolites with validated MS/MS extraction 
masses. As SWATHTM MS has a higher LOQ than MRM, it may not be suitable for 
analysing small volume samples such as tear fluid. 
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6. Conclusion and Future Outlook 
 
This thesis reports the first comprehensive characterisation of the human tear 
metabolome using IDA LC-MS/MS with RP and HILIC chromatography coupled to 
the positive and negative ionisation polarities. A total of 60 metabolites were 
identified, and 44 were detected for the first time in tear fluid. These results 
demonstrate the applicability of tear fluid metabolites in studying eye diseases. 
Several challenges were faced in metabolite identification; these apply to any 
experiment in global metabonomic profiling on an LC-MS/MS platform. Some 
examples of possible misannotations that are described in this thesis, such as in-
source fragmentation of inosine, are also mentioned in a recent publication that 
examined such misannotations in detail (178).  
 
Besides the aforementioned ionisation artefacts, non-biological artefacts derived 
from sample collection and extraction processes, such as coatings of blood 
collection tubes, surfactants and detergents may also contribute to m/z-RT 
features in metabonomic analysis (179). Unlike in proteomic analysis where data 
quality can be assessed by the number of identified proteins, the number of 
features obtained in LC-MS/MS-based metabonomics does not reflect the 
coverage of the metabolome. Mahieu et al. have recently developed a workflow 
for credentialing m/z-RT features using E. coli cultures grown in regular (control) 
and 13C-enriched media (180). Features of biological origin were identified from 
isotope-intensity analysis of standing samples consisting of control: 13C-labeled 
mixed at specific ratios. The use of such credentialing workflows would provide a 
common benchmark in assessing metabolome coverage in LC-MS/MS-based 
metabonomics.  
 98 
The second chapter of this thesis identified dose-dependent accumulation of 
glycerophosphcholine with increasing hyperosmotic stress using an in vitro model 
of dry eye disease. With the integration of proteomic data, O-linked β-N-
acetylglucosamine glycosylation was identified as a potential therapeutic target for 
dry eye disease. Experiments targeting the activity of choline transporters and 
enzymes in the synthesis pathway of glycerophosphcholine could also be 
performed to establish their effects on intracellular glycerophosphocholine levels. 
The levels O-linked β-N-acetylglucosamine glycosylation could also be modulated 
to investigate its effects on cell survival. It is also pertinent to investigate the tear 
fluid concentration of glycerophosphocholine, UDP-N-acetylglucosamine and other 
perturbed metabolites in healthy volunteers and patients with dry eye to establish 
their relevance as biomarkers of dry eye or ocular surface inflammation.  
 
Lastly, plasma metabotyping of DR using GC-MS found metabolite markers of DR 
that were independent of known risk factors. These findings should be validated in 
a larger cohort involving participants from other ethnic groups. Collection of 
fasting blood samples is preferred over random sampling to reduce variability. A 
prospective cohort study is needed to identify patterns in metabolic perturbations 
that could be predictive of the rate of disease progression. In such a study, diabetic 
patients with no DR and healthy volunteers should be recruited together. Plasma 
samples collected at the start of the study should be performed to establish 
baseline levels of plasma metabolites. Should resources permit, the participants 
should be examined at multiple follow-ups (e.g. every two years up to ten years). It 
is important to first establish the presence of distinct clusters of disease 
progression that were first identified by Zavrelova et al. (142), before investigating 
the correlations between such clusters with the plasma metabonomic profiles.   
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8.1. Supplementary Methods in In Vitro Model of Dry 
Eye Disease 
 
8.1.1. Cell Viability Assay 
Three sets of cells were grown and treated in black 96-well plates. The average cell 
viability under each condition was determined with CellTiter-Glo Luminescent Cell 
Viability Assay (Promega, Madisin, WI, USA). 
 
8.1.2. Sample Preparation for Global Metabonomic Analysis 
Five sets of cells were grown in 6-well plates and treated with control, T1 and T2 
treatment media. Cells were washed twice with cold PBS (4 °C) and lysed by the 
addition of 1.5 mL of methanol maintained at −80 °C. Plates were scraped over a 
dry ice bath, and each lysate was transferred to a microcentrifuge tube. Lysates 
were vortex-mixed at 1200 rpm for 5 min and centrifuged for 10 min at 16,000 g 
(4 °C). The supernatants were concentrated in a vacuum concentrator and freeze-
dried subsequently.  
 
8.1.3. Sample Preparation for Targeted Metabolite Analysis 
 Three sets of cells were grown in 6-well plates and treated with control, T1 and T2 
treatment media. Cells were dissociated from the plates with TrypLE express 
(Invitrogen), collected in microcentifuge tubes and re-suspended in 500 µL of PBS. 
The cell suspension of each sample was divided into two aliquots of 450 uL and 50 
uL respectively, and cells in each aliquot were pelleted.   
 111 
Cells from the 50 uL aliquot were lysed in 40 uL of RIPA buffer containing 1× 
protease inhibitor (Thermo Scientific). Samples were vortexed briefly, placed in a 
cold ultrasonic bath for 30 s and mixed on an orbital shaker for 10 min. Lysates 
were centrifuged for 10 min at 15,000 g (4 °C) and the protein concentration of 
each supernatant was quantified with a DC protein assay kit (Bio-Rad Laboratories, 
Hercules, CA).  
 
Cells from the 450 uL aliquot were lysed in 400 uL of 3:2 water/methanol 
containing 1 mM K2EDTA and 10 mM ammonium bicarbonate in. Samples were 
vortexed briefly, snap-frozen in liquid nitrogen, thawed and homogenised with a 
hand-held homogeniser for 1 min. 600 uL of methanol was added and lysates were 
centrifuged for 10 min at 15,000 g (4 °C). The supernatants were dried and re-
constituted in 30 uL of 9:1 methanol/water for targeted analysis. Metabolite levels 
in lysates were normalised to protein content. 
 
8.1.4. Sample Preparation for Global Proteomic Analysis 
Three sets of cells were grown in 6-well plates and treated with control, T1 and T2 
treatment media. Cells were washed twice with cold PBS (4 °C) prior to harvesting. 
Flasks were scraped immediately after the addition of 1.5 mL of RIPA buffer with 
1× protease inhibitor (Thermo Scientific). Cell suspensions were transferred to 
microcentrifuge tubes and gently agitated for 2 h at 4 °C to complete lysis. Lysates 
were centrifuged for 10 min at 16,000 g (4 °C) and the protein concentration of 




Cell lysates containing 50 µg of protein were reconstituted in 22 µL of 50 mM 
ammonium bicarbonate solution from the FASP kit denatured with 6 μL of 10% 
sodium dodecyl sulphate and 2 μL of tris(2-carboxyethyl) phosphine from the 
iTRAQ kit at 60oC for 1 h. The reduced proteins were then transferred to 30 kD cut-
off membrane cartridge from the FASP kit and centrifuged twice with 200 µL of 
urea solution from the FASP kit at 14,000 g for 15 min (25oC). The reduced proteins 
were then incubated with 10 µL of 10× iodoacetamide from the FASP kit for 20 min 
in the dark and centrifuged twice at 14,000 g with 100 µL of urea solution, 
followed by ammonium bicarbonate solution. The samples were digested on-
catridge with trypsin (AB Sciex) (1:25 trypsin/protein ratio) for 16 h at 37 °C. 
Digested peptides were eluted by centrifugation with 40 µL of ammonium 
bicarbonate solution, then with 50 µL of sodium chloride solution from the FASP 
kit. Digestion was quenched with 30 µL of 10% formic acid and samples were dried 
in a vacuum concentrator. 
 
Samples were reconstituted in 20 µL of dissolution buffer from the iTRAQ kit. Each 
vial of iTRAQ reagent was reconstituted with 70 µL of ethanol. The respective 
iTRAQ reagents were then added to samples (one vial per 50 µg protein) and 
mixed for 2 hours at 25 °C to label the peptides. The labelled samples were then 
pooled together, dried and desalted on ultramicro spin columns (The Nest Group) 




8.1.5. Peak Finding and Alignment of Metabonomic Data 
 
Table 8.1. MarkerView parameters for peak finding and alignment of LC-MS/MS 










Subtraction offset/scans 3 
Multiplication factor 1.2 




RT window/min 0.6 to 18 
Noise threshold/counts 20 5 
Peak alignment 
RT tolerance/min 0.15 0.20 
Mass tolerance/ppm 10 
Minimum Number of Samples 5 
Minimum Threshold 20 5 
 
 
8.1.6. Targeted Metabonomic Analysis 
 
Table 8.2. Optimised MRM parameters for validation of metabolite markers. 
Metabolite Q1 (m/z) Q3 (m/z) DP (V) CE (V) CXP (V) 
Carnitine 162.1 103.0 60 23 12 
Glycerophosphocholine 258.1 104.0 70 22 9 




8.2. Supplementary Results for Metabotyping of 
Diabetic Retinopathy 
 
Table 8.3 Comparison of clinicopathological characteristics in subset of 
participants with HbA1c levels at 10% or below. 
Clinical Characteristics DR Non-DR P-value 
N 30 39 - 
Gender 12 M 22 M 0.176† 
Age (years) 61 (54–69 ) 62 (52–69 ) 0.807‡ 
Diastolic BP (mm Hg) 72 (67–79 ) 77 (68–83 ) 0.153‡ 
Systolic BP (mm Hg) 140 (131–156 ) 133 (122–146 ) 0.206‡ 
BMI (kg/m2) 25.3 (23.1–29.4 ) 28.7 (23.3–30.3 ) 0.186‡ 
Serum creatinine (µM) 84 (69–125 ) 79 (58–124 ) 0.181‡ 
Blood glucose, random 
(mM) 
9.3 (6.5–11.9 ) 8.2 (6.9–11.0 ) 0.599‡ 
Total cholesterol (mM) 4.42 (3.93–5.32 ) 4.32 (3.64–5.19 ) 0.498‡ 
LDL cholesterol (mM) 2.73 (2.15–3.44 ) 2.56 (2.07–3.27 ) 0.603‡ 
HDL cholesterol (mM) 1.01 (0.84–1.25 ) 1.01 (0.83–1.23 ) 0.950‡ 
Triglycerides (mM) 1.79 (1.30–2.54 ) 1.32 (0.93–2.07 ) 0.121‡ 
Blood HbA1c (%) 7.9 (7.1–8.8 ) 7.3 (6.5–8.0 ) 0.055‡ 
Duration of diabetes (years) 13 (7–22 ) 11 (6–20 ) 0.364‡ 
Urine ACR (µg/mg 
creatinine) 
46.0 (14.6–123.8 ) 24.8 (12.3–57.0 ) 0.156‡ 
eGFR (mL/min/1.73 m2) 71.0 (43.8–95.2 ) 87.1 (48.4–99.9 ) 0.196‡ 
Microalbuminuria 14 14 0.336† 
Macroalbuminuria 4 2 0.230† 
Chronic Kidney Disease§ 12 11 0.303† 
On Diabetes Medication 25 32 0.889† 
* Values indicate median with interquartile range, where applicable 
† Pearson chi-square test  
‡ Mann-Whitney U test 




Table 8.4 Comparison of clinicopathological characteristics in subset of 
participants with HbA1c levels between 6 to 10%. 
Clinical Characteristics DR Non-DR P-value 
N 29 34 - 
Gender 11 M 19 M 0.155† 
Age (years) 61 (55–69 ) 61 (52–67 ) 0.385‡ 
Diastolic BP (mm Hg) 72 (67–78 ) 75 (68–81 ) 0.124‡ 
Systolic BP (mm Hg) 141 (131–156 ) 133 (122–145 ) 0.097‡ 
BMI (kg/m2) 25.6 (23.1–29.5 ) 28.6 (23.3–30.2 ) 0.224‡ 
Serum creatinine (µM) 85 (69–129 ) 77 (58–104 ) 0.126‡ 
Blood glucose, random 
(mM) 
9.6 (6.5–12.1 ) 8.5 (7.0–11.2 ) 0.719‡ 
Total cholesterol (mM) 4.43 (4.01–5.33 ) 4.22 (3.69–5.32 ) 0.500‡ 
LDL cholesterol (mM) 2.78 (2.16–3.45 ) 2.54 (2.07–3.12 ) 0.508‡ 
HDL cholesterol (mM) 1.03 (0.83–1.26 ) 1.00 (0.86–1.24 ) 0.915‡ 
Triglycerides (mM) 1.79 (1.38–2.57 ) 1.35 (0.94–2.33 ) 0.151‡ 
Blood HbA1c (%) 7.9 (7.1–8.8 ) 7.4 (6.8–8.1 ) 0.161‡ 
Duration of diabetes (years) 13 (7–22 ) 10 (6–18 ) 0.236‡ 
Urine ACR (µg/mg 
creatinine) 
46.0 (17.7–129.1 ) 26.1 (11.5–52.8 ) 0.086‡ 
eGFR (mL/min/1.73 m2) 63.3 (42.4–94.7 ) 88.1 (55.2–100.3 ) 0.095‡ 
Microalbuminuria 14 12 0.216† 
Macroalbuminuria 4 2 0.286† 
Chronic Kidney Disease§ 12 9 0.211† 
On Diabetes Medication 24 30 0.536† 
* Values indicate median with interquartile range, where applicable 
† Pearson chi-square test  
‡ Mann-Whitney U test 








Table 8.5 Odd ratios metabolite markers adjusted for age, gender and diastolic BP. 
Metabolite 
Odds ratio, per s.d. increment in metabolite peak area (95% CI) 
Basic Model +Age + Gender + Diastolic BP 
1,5-Anhydroglucitol 0.37 (0.19–0.65)* 0.37 (0.19–0.65)* 0.36 (0.18–0.63)* 0.30 (0.14–0.54)*‡ 
1,5-Gluconolactone 2.40 (1.38–4.65)* 2.50 (1.42–4.95)* 2.49 (1.40–4.94)* 2.50 (1.43–4.88)* 
2-Deoxyribonic acid 2.08 (1.25–3.76)* 2.17 (1.29–3.98)* 2.08 (1.25–3.76)* 2.15 (1.29–3.91)* 
3,4-Dihydroxybutyric acid 1.61 (1.01–2.70)† 1.71 (1.05–2.92)* 1.61 (1.01–2.69)† 1.63 (1.02–2.73)* 
3-Methyl-2-oxovaleric acid 0.81 (0.50–1.27) 0.72 (0.43–1.19) 0.81 (0.49–1.29) 0.78 (0.48–1.24) 
α-Ketoisovalerate 0.58 (0.34–0.93)* 0.53 (0.30–0.88)* 0.58 (0.34–0.93)* 0.55 (0.32–0.90)* 
Erythritol 1.68 (1.04–2.85)* 1.74 (1.07–2.98)* 1.68 (1.04–2.86)* 1.73 (1.08–2.94)* 
Erythronic acid 1.57 (0.97–2.71)† 1.65 (1.00–2.90)† 1.57 (0.97–2.71)† 1.59 (0.98–2.75)† 
Gluconic acid 2.65 (1.50–5.33)* 2.64 (1.49–5.32)* 2.66 (1.50–5.37)* 2.79 (1.57–5.61)* 
Glutamine 0.51 (0.28–0.86)* 0.51 (0.28–0.85)* 0.51 (0.28–0.86)* 0.53 (0.30–0.88)* 
Hippuric acid 1.71 (1.05–2.98)* 1.94 (1.14–3.61)* 1.72 (1.05–3.00)* 1.74 (1.08–3.02)* 
Inositol phosphate 1.26 (0.80–2.03) 1.28 (0.81–2.08) 1.26 (0.79–2.07) 1.32 (0.84–2.14) 
Lactose/Cellobiose 1.78 (1.10–3.01)* 1.88 (1.15–3.25)* 1.79 (1.10–3.04)* 1.85 (1.14–3.14)* 
Maltose/Trehalose 2.14 (1.29–3.84)* 2.13 (1.28–3.82)* 2.18 (1.31–3.94)* 2.33 (1.39–4.20)* 
Mannose 1.81 (1.09–3.27)* 1.82 (1.07–3.38)* 1.86 (1.10–3.44)* 1.90 (1.14–3.47)* 
Myo-inositol 1.60 (0.99–2.76)† 1.70 (1.03–3.02)* 1.60 (0.99–2.76)† 1.69 (1.04–2.96)* 
Ribose 1.65 (1.02–2.80)* 1.71 (1.05–2.95)* 1.67 (1.03–2.85)* 1.74 (1.09–2.95)* 
Urea 1.95 (1.18–3.48)* 2.28 (1.32–4.30)* 1.95 (1.18–3.48)* 2.05 (1.22–3.71)* 










Table 8.6 Odd ratios metabolite markers adjusted for total cholesterol, LDL cholesterol and HDL cholesterol. 
Metabolite 
Odds ratio, per s.d. increment in metabolite peak area (95% CI) 
Basic Model + Total Cholesterol +LDL Cholesterol + HDL Cholesterol 
1,5-Anhydroglucitol 0.37 (0.19–0.65)* 0.36 (0.18–0.63)* 0.36 (0.19–0.63)* 0.35 (0.18–0.61)* 
1,5-Gluconolactone 2.40 (1.38–4.65)* 2.58 (1.47–5.01)* 2.62 (1.50–5.12)* 2.55 (1.47–4.93)* 
2-Deoxyribonic acid 2.08 (1.25–3.76)* 2.21 (1.33–4.00)* 2.30 (1.37–4.20)* 2.20 (1.32–3.99)* 
3,4-Dihydroxybutyric acid 1.61 (1.01–2.70)† 1.65 (1.04–2.76)* 1.68 (1.05–2.80)* 1.67 (1.05–2.78)* 
3-Methyl-2-oxovaleric acid 0.81 (0.50–1.27) 0.73 (0.45–1.15) 0.73 (0.45–1.15) 0.75 (0.47–1.18) 
α-Ketoisovalerate 0.58 (0.34–0.93)* 0.51 (0.29–0.84)* 0.52 (0.30–0.84)* 0.54 (0.31–0.87)* 
Erythritol 1.68 (1.04–2.85)* 1.80 (1.12–3.06)* 1.85 (1.14–3.15)* 1.78 (1.11–3.00)* 
Erythronic acid 1.57 (0.97–2.71)† 1.70 (1.04–2.96)* 1.74 (1.07–3.06)* 1.65 (1.02–2.83)† 
Gluconic acid 2.65 (1.50–5.33)* 2.73 (1.54–5.47)* 2.75 (1.55–5.53)* 2.79 (1.57–5.61)* 
Glutamine 0.51 (0.28–0.86)* 0.55 (0.31–0.92)* 0.55 (0.30–0.91)* 0.51 (0.28–0.86)* 
Hippuric acid 1.71 (1.05–2.98)* 1.82 (1.11–3.19)* 1.85 (1.13–3.28)* 1.77 (1.10-3.08)* 
Inositol phosphate 1.26 (0.80–2.03) 1.44 (0.91–2.35) 1.43 (0.90–2.32) 1.36 (0.87–2.18) 
Lactose/Cellobiose 1.78 (1.10–3.01)* 1.92 (1.19–3.28)* 1.98 (1.22–3.39)* 1.90 (1.18–3.20)* 
Maltose/Trehalose 2.14 (1.29–3.84)* 2.04 (1.25–3.59)* 2.05 (1.25–3.61)* 2.10 (1.28–3.68)* 
Mannose 1.81 (1.09–3.27)* 1.64 (1.00–2.93)† 1.66 (1.00–2.96)† 1.71 (1.05–3.04)* 
Myo-inositol 1.60 (0.99–2.76)† 1.75 (1.08–3.03)* 1.80 (1.11–3.13)* 1.74 (1.08–3.00)* 
Ribose 1.65 (1.02–2.80)* 1.69 (1.05–2.89)* 1.71 (1.07–2.93)* 1.71 (1.07–2.90)* 
Urea 1.95 (1.18–3.48)* 2.19 (1.32–3.92)* 2.23 (1.34–4.00)* 2.05 (1.25–3.64)* 
* P( model )< 0.05 
† P(model)<0.1 
‡ P(likelihood-ratio)<0.05 
§ P(likelihood-ratio)<0.1 
 
